预约演示
更新于：2026-05-23
Rilpivirine Hydrochloride
盐酸利匹韦林
更新于：2026-05-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-05-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C22H19ClN6 |
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N |
CAS号700361-47-3 |
关联
114
项与 盐酸利匹韦林 相关的临床试验NCT06336434
Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults With HIV-1
This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.
开始日期2025-05-01 |
NCT06646562
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.
开始日期2025-03-03 |
申办/合作机构 |
TCTR20250218001
Changes in sleep quality following a switch of antiretroviral regimen from three to two drugs: A comparative study between dolutegravir and lamivudine (DTG + 3TC) and dolutegravir and rilpivirine (DTG + RPV)
开始日期2025-02-04 |
申办/合作机构- |
100 项与 盐酸利匹韦林 相关的临床结果
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的转化医学
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的专利（医药）
登录后查看更多信息
1,706
项与 盐酸利匹韦林 相关的文献（医药）2026-12-31·HIV Research & Clinical Practice
Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure
Article
作者: Sram, Krystof ; Lhotan, Jakub ; Jilich, David ; Sevela, Stanislav ; Rozsypal, Hanus
INTRODUCTION:
In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible. Long-acting cabotegravir/rilpivirine (CAB/RPV LA) is approved for virologically suppressed individuals pretreated with oral therapy, but data on its use in treatment-naïve, critically ill patients with absent enteral absorption are extremely limited.
CLINICAL PRESENTATION:
We report a 26-year-old male admitted with fulminant hypertriglyceridaemic necrotizing pancreatitis complicated by abdominal compartment syndrome, multiple laparotomies, open abdomen with enteric fistulae, short bowel syndrome type I, chronic intestinal failure requiring parenteral nutrition, portal vein thrombosis, and prolonged intensive care. HIV-1 infection was diagnosed early (HIV RNA 5,000 copies/mL; CD4+ 780 cells/µL). Within three months, HIV RNA rose to 320,000 copies/mL and CD4+ declined to 570 cells/µL. Given absent gastrointestinal passage, standard ARV was initially deferred, but rapid virological rebound necessitated urgent treatment. An off-label fully parenteral regimen was initiated: intravenous zidovudine (AZT) with intramuscular CAB/RPV LA. Therapy was well tolerated alongside surgery, parenteral nutrition, antimicrobials, and anticoagulation. HIV RNA decreased to <20 copies/mL within 65 days and remained suppressed, with CD4+ recovery. Intravenous AZT was discontinued after 35 days, and CAB/RPV LA continued as maintenance during recovery and home parenteral nutrition.
DISCUSSION:
Fully parenteral ARV, including CAB/RPV LA, may provide a safe and effective bridge to durable viral suppression in patients with absolute contraindications to oral therapy, warranting further evaluation.
2026-07-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context
Article
作者: Gagliardini, Roberta ; Marchetti, Giulia ; Squillace, Nicola ; Giacomelli, Andrea ; Monforte, Antonella d'Arminio ; Antinori, Andrea ; Raccagni, Angelo Roberto ; Bana, Nicholas Brian ; Muccini, Camilla ; Mazzotta, Valentina ; Tavelli, Alessandro ; Saracino, Annalisa
The aim of this study was to describe virological outcomes in people with HIV (PWH) after discontinuation of long-acting (LA) cabotegravir (CAB) plus rilpivirine (RPV). All PWH enrolled in the Icona Cohort who discontinued CAB/RPV LA and had at least one follow-up after discontinuation were included. A total of 84 out of 805 (10.4%) PWH discontinued CAB/RPV, mainly due to toxicity or adverse events (67.9%). Most individuals (72.6%) returned to the same oral antiretroviral regimen used prior LA therapy. The 12-month cumulative probability of discontinuing oral ART after CAB/RPV was 19.9% (95% confidence interval [CI] 11.9-32.2%). After switching back to oral ART all individuals except one maintained or achieved HIV RNA levels below 50 copies/mL. These findings suggest that PWH who discontinue LA CAB/RPV and resume oral ART maintain or achieve high rates of virologic suppression.
2026-05-01·Journal of Stroke & Cerebrovascular Diseases
Ropivacaine attenuates cerebral ischemia-reperfusion injury in young male mice by reducing endothelial oxidative stress through activation of the Htr7/cAMP-PKA signaling
Article
作者: Wang, Bo ; Ni, Yanglin ; Hou, Yayun ; Zhang, Haoxi ; Shan, Yongzhuang ; Xu, Hao ; Zhai, Wenshan
OBJECTIVE:
Cerebral ischemia-reperfusion injury (CIRI) involves oxidative stress and endothelial dysfunction. The objective of this study is to elucidate the underlying mechanisms through which ropivacaine (RPV) mitigates the CIRI.
METHODS:
A transient middle cerebral artery occlusion/reperfusion (tMCAO/R) model was established in 8-week-old male mice to mimic CIRI in vivo. Mice were treated with RPV or positive control edaravone. Cortical injury was evaluated via TTC staining, hematoxylin-eosin staining, and TUNEL assays. Levels of reactive oxygen species (ROS), malondialdehyde (MDA), and superoxide dismutase (SOD) in cortical tissue were measured. In vitro, bEnd.3 cells were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) and treated with RPV. Cell viability was evaluated, while oxidative stress markers ROS, MDA, and SOD were assayed. Western blotting (WB) evaluated 5-hydroxytryptamine receptor 7 (Htr7) and cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) signaling proteins in cortical tissue and bEnd.3 cells. Gene knockdown of Htr7 was performed to validate the role of Htr7/cAMP-PKA in the in vitro and in vivo effects of RPV.
RESULTS:
RPV upregulated Htr7 expression in mouse cortical tissues surrounding the infarct and alleviated CIRI, as shown by reduced infarct volume, lower ROS and MDA levels, and increased SOD activity. RPV reduced oxidative stress in bEnd.3 cells and activated the cAMP-PKA pathway. Knockdown of Htr7 attenuated the protective effects of RPV, while cAMP-PKA activation suppressed endothelial oxidative stress.
CONCLUSION:
RPV alleviates CIRI by upregulating Htr7 expression, activating the cAMP-PKA signaling, and reducing endothelial oxidative stress.
370
项与 盐酸利匹韦林 相关的新闻（医药）2026-05-20
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts
Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety
,
and vonoprazan use post endoscopic submucosal dissection (ESD)
Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA
®
(vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts across gastroesophageal reflux disease (GERD),
Helicobacter pylori
(
H. pylori
) eradication, long-term safety, and post endoscopic procedural care, reflecting the growing scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class in GI medicine.
“The breadth of data presented at DDW 2026 reflects the significant scientific interest in vonoprazan across multiple acid-related conditions,” said
Steve Basta, President and Chief Executive Officer of Phathom.
“We are encouraged by the level of independent scientific engagement and the broad interest among researchers to evaluate vonoprazan in a range of conditions. The research highlighted at this year’s meeting adds to the growing scientific understanding of vonoprazan across multiple areas of GI medicine.”
Key data presented at DDW 2026 include:
Meta-analysis of data from randomized controlled trials evaluating healing outcomes in patients with severe (LA Grade C and D) erosive esophagitis (Erosive GERD) treated with vonoprazan compared to the proton pump inhibitor (PPI) lansoprazole
Analyses from the Phase 3 pHalcon-NERD-301 study evaluating both heartburn and regurgitation symptoms in patients with Non-Erosive GERD (NERD) treated with vonoprazan versus placebo, as measured by the validated PAGI-SYM patient-reported outcome instrument
Real-world data evaluating vonoprazan in patients with PPI-refractory GERD following laparoscopic sleeve gastrectomy
Multiple independent meta-analyses evaluating
H. pylori
eradication rates with vonoprazan-based regimens, including a network meta-analysis of 77 randomized controlled trials comparing treatment strategies
Real-world propensity-matched cohort analyses evaluating safety outcomes associated with vonoprazan and traditional PPIs, including rates of vitamin B12 deficiency, hypomagnesemia, and
Clostridioides difficile
(
C. diff
) infection
Two independent systematic reviews and meta-analyses evaluating delayed post-procedural bleeding following endoscopic submucosal dissection (ESD) in patients treated with vonoprazan compared to PPIs
Post hoc analyses from the multicenter, prospective, real-world observational study evaluating vonoprazan in Chinese patients with reflux esophagitis across patient subpopulations including elderly patients and those with comorbid anxiety or depression
Vonoprazan Abstracts Presented at DDW 2026:
28 independent abstracts reflect investigator-initiated research conducted by academic and clinical scientists across the United States, Europe, Asia, and South America:
Independent Research on Vonoprazan:
GERD
Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Patients with Grade C and D Erosive Esophagitis: A Meta-Analysis
(
He E et al.
; Tu1173)
Use Morning or/and Evening Dosing of Vonoprazan for Gastroesophageal Reflux Disease: An Interim Analysis for a Randomized Crossover Trial
(
Wang D et al.
; Tu1163)
Real-World Prescription Patterns of Potassium-Competitive Acid Blockers (PCABs) in Erosive Esophagitis: A New Era in Acid Suppression
(
Chalhoub M et al.
; Tu1167)
Effectiveness and Safety of Vonoprazan in Elderly Chinese Patients with Gastroesophageal Reflux Disease: A Post Hoc Analysis of the VIEW Study
(
Liang K et al.
; Tu1165)
Effectiveness of Vonoprazan on Symptom Relief in Gastroesophageal Reflux Disease Patients with Anxiety or Depression: A Post Hoc Analysis of the VIEW Study
(
Liang K et al.
; Tu1168)
Vonoprazan Improves GERD Symptoms and Heals Erosive Esophagitis in Patients with Gastric Sleeve Refractory to High Dose PPI
(
Cricco-Lizza E et al.
; Presentation 972)
Safety
Real World Evaluation of Adverse Events Associated with Vonoprazan Compared with Traditional Proton Pump Inhibitors
(
Al Momani Z et al.
; Su1277)
Long Term Safety of Vonoprazan Compared with Proton Pump Inhibitors: A Large Multi-Center Real World Propensity Matched Cohort
(
Alsafi W et al.
; Tu1221)
The Risk of Clostridioides Difficile Infection with Vonoprazan Compared to Proton Pump Inhibitors: A Large Multi-Center Cohort Study
(
Cohen E et al.
; Sa1333)
Potassium-Competitive Acid Blockers and Risk of Small Intestinal Bacterial Overgrowth and Nutrient Deficiencies: A Global Real-World Study
(
Luo A et al.
; Su1273)
Vonoprazan Does Not Increase the Incidence of Benign Gastric Polyps Compared with Proton Pump Inhibitors
(
Simadibrata D et al.
; 1123)
PCABs Are Associated with Low Rates of Short-Term Adverse Events: A Global Cohort Study Comparing PCABs Versus PPIs
(
Lee ME et al.
; Poster 963)
H. pylori
Eradication
First-Line Empirical Eradication Therapy for H. pylori Infection: Experience from 1,500 Cases of the Brazilian H. pylori Registry
(
Friche Passos M et al.
; Tu1224)
Efficacy of Potassium-Competitive Acid Blocker (PCAB)-Based Therapies for H. pylori Infection: A Network Meta-Analysis of 77 Randomized Controlled Trials
(
Song Z et al.
; Tu1223)
Comparative Efficacy and Safety of Vonoprazan-Based Dual Therapy Versus Bismuth-Based Quadruple Therapy for H. pylori: A GRADE-Assessed Meta-Analysis with Trial Sequential Analysis
(
Navabi S et al.
; Tu1222)
Vonoprazan Based Therapy Outperforms Proton Pump Inhibitor Regimens for H. pylori Eradication: A Review of Six Meta-Analyses
(
Chakinala R et al.
; Tu1219)
Simplicity Without Compromise: An Updated Meta-Analysis of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapy for H. pylori Eradication
(
Zahid M et al.
; Tu1205)
Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis
(
Haider A et al.
; Tu1204)
Comparative Efficacy and Safety of Vonoprazan Triple Therapy Versus PPI and Bismuth Based Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis
(
Gundapaneni S et al.
; Tu1200)
Ten Versus Fourteen Days of Vonoprazan-Based Therapy for H. pylori: A Systematic Review and Meta-Analysis
(
Alsaleh T et al.
; Tu1211)
Efficacy and Safety of 14-Day Bismuth-Containing Quadruple Therapy with Low-Dose Vonoprazan Versus Esomeprazole for H. pylori Eradication: A Real-World Multicenter Study
(
Lin H et al.
; Tu1213)
Efficacy and Safety of Vonoprazan Dual Versus Quadruple Therapy for H. pylori Second-Line Treatment: A Real-World Study
(
Li P et al.
; Tu1209)
P-CAB/Minocycline/Furazolidone/Bismuth Quadruple Regimen for Refractory H. pylori Infection: A Multicenter Study
(
Li P et al.
; Tu1199)
Vonoprazan Plus High-Dose Amoxicillin Dual Therapy Versus PPI-Based Low-Dose Amoxicillin Quadruple Therapy for H. pylori: A Systematic Review and Meta-Analysis
(
Patel R et al.
; Tu1220)
Vonoprazan-Tetracycline Dual Therapy as a Simplified Rescue Regimen for Helicobacter Pylori: A Randomized Non-Inferiority Trial
(
Li J et al.
; Poster 437)
Transforming Amoxicillin Therapy into a Grade-A Eradication Regimen with Vonoprazan and Bismuth: A Multicenter Randomized Trial
(
Hsu P et al.
; Poster 861)
Vonoprazan Use Post Endoscopic Submucosal Dissection
Potassium-Competitive Acid Blockade After ESD: Does Vonoprazan Outperform PPIs? A Systematic Review and Meta-Analysis
(
Ginnaram S et al.
; Su1226)
Vonoprazan Versus Proton Pump Inhibitors for Prevention of Delayed Bleeding After Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis
(
Singh S et al.
; Sa2164)
Phathom-Sponsored Research on Vonoprazan:
Assessment of Heartburn and Regurgitation in Symptomatic Non-Erosive Gastroesophageal Reflux Disease Patients on Vonoprazan: Exploratory Analysis of PAGI-SYM
[Poster of Distinction]
(
Fass R et al.
; Tu1159)
Patient Reported Outcomes, Patient Experience, and Treatment Satisfaction with Prescription Treatments for Gastroesophageal Reflux Disease: A Real-World Survey of U.S. Adults
(
Shaheen N et al.
; Tu1164)
A Phase 1, Open-Label Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg QD or BID
(
Chang YM et al.
; Su1272)
About VOQUEZNA
®
(vonoprazan)
VOQUEZNA
®
(vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, the relief of heartburn associated with Erosive GERD, the relief of heartburn associated with Non-Erosive GERD, and for the treatment of
H. pylori
infection in combination with either amoxicillin or amoxicillin and clarithromycin. Any other uses of vonoprazan as described in the research presented at DDW are investigational in the U.S. and Phathom makes no representations concerning the safety or efficacy of such investigational uses. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and numerous other countries in Asia and Latin America.
INDICATIONS AND USAGE
VOQUEZNA
®
(vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:
for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD.
to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD.
for the relief of heartburn associated with Non-Erosive GERD.
in combination with amoxicillin and clarithromycin for the treatment of
Helicobacter pylori (H. pylori)
infection.
in combination with amoxicillin for the treatment of
H. pylori
infection.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.
For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information.
WARNINGS AND PRECAUTIONS
Presence of Gastric Malignancy:
In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.
Acute Tubulointerstitial Nephritis:
Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.
Clostridioides difficile
-Associated Diarrhea:
Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of
Clostridioides difficile
-associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.
CDAD has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with VOQUEZNA, refer to Warnings and Precautions section of the corresponding prescribing information.
Bone Fracture:
Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.
Severe Cutaneous Adverse Reactions (SCAR):
Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.
Vitamin B12 (Cobalamin) Deficiency:
Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.
Hypomagnesemia and Mineral Metabolism:
Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.
Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.
Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.
Interactions with Diagnostic Investigations for Neuroendocrine Tumors:
Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high.
Fundic Gland Polyps:
Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.
ADVERSE REACTIONS:
Healing of Erosive GERD:
The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).
Maintenance of Healed Erosive GERD:
The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).
Relief of Heartburn Associated with Non-Erosive GERD:
The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%).
Treatment of
H. Pylori
Infection (VOQUEZNA and Amoxicillin):
The most common adverse reactions (≥2% in any treatment arm) include diarrhea (5%), abdominal pain (3%), vulvovaginal candidiasis (2%), nasopharyngitis (2%), dysgeusia (1%), headache (1%), and hypertension (1%).
Treatment of
H. Pylori
Infection (VOQUEZNA, Amoxicillin and Clarithromycin):
The most common adverse reactions (≥2% in any treatment arm) include dysgeusia (5%), diarrhea (4%), vulvovaginal candidiasis (3%), headache (3%), abdominal pain (2%), hypertension (2%), and nasopharyngitis (<1%).
For more information on adverse reactions and laboratory changes with amoxicillin or clarithromycin, refer to Adverse Reactions section of the corresponding prescribing information.
DRUG INTERACTIONS
VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.
For information about drug interactions, contraindications, and warnings and precautions of antibacterial agents (amoxicillin or clarithromycin) indicated in combination with VOQUEZNA, refer to their corresponding prescribing information.
USE IN SPECIFIC POPULATIONS
Pregnancy:
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting
Lactation:
There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition.
Renal Impairment:
For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with severe renal impairment.
Hepatic Impairment:
For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with moderate to severe hepatic impairment.
You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888- 775-PHAT (7428) or FDA at 1-800-FDA-1088 or
Please
click here
to see full Prescribing Information for VOQUEZNA.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA
®
(vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA
®
TRIPLE PAK
®
(vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA
®
DUAL PAK
®
(vonoprazan tablets, amoxicillin capsules) for the treatment of
H. pylori
infection in adults. For more information about Phathom, visit the company’s website at follow on LinkedIn and X.
About DDW
Digestive Disease Week
®
(DDW) is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting.
Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: the significance, interpretation and potential implications of data presented at DDW 2026; the scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class; the potential efficacy, safety and tolerability pro VOQUEZNA® (vonoprazan); and the relevance and applicability of analyses, meta-analyses, real-world studies, post hoc analyses and investigator-initiated research discussed in this press release. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: the data, analyses and other information presented at DDW 2026 may not be predictive or indicative of future research findings, clinical outcomes or real-world results; exploratory analyses, post hoc analyses, meta-analyses, retrospective studies and investigator-initiated research are subject to inherent limitations and may be interpreted differently following additional review, analysis or peer review; additional data or analyses may alter the interpretation or significance of results discussed in this press release; regulatory review may differ from or not support the conclusions suggested by the data discussed in this press release or future data, analyses; and market acceptance for VOQUEZNA from healthcare professionals, patients and payors in the indications for which it is approved may be lower than we anticipate. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
05/26 US-VPZ-26-0175
临床结果临床3期上市批准临床1期
2026-05-19
The Journal of Infectious Diseases. Volume 233 Issue 1
传染病杂志 233卷 1期
https://academic.oup.com/jid/issue/
Editorial（社论）
1
Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli (STEC) Without Inducing Toxin Production
用于控制产志贺毒素大肠杆菌（STEC）且不诱导毒素产生的烈性噬菌体
Glen D Armstrong
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 1–2, https://doi.org/10.1093/infdis/jiaf036
Invited Perspective（特邀观点）
2
With All Good Intentions: How CDC Decisions Harmed Science and People
John Weiser
好心办坏事：美国疾控中心（CDC）的决策如何损害了科学和民众
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 3–5, https://doi.org/10.1093/infdis/jiaf584
Perspectives（观点）
3
Persistence Is Resistance: The Fight to End the HIV Epidemic Hangs in the Balance
坚持即抵抗：结束艾滋病流行的斗争悬而未决
Colleen F Kelley and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 6–8, https://doi.org/10.1093/infdis/jiaf389
Special Collection on Contemporary Research on Antimicrobial Resistance（抗菌药物耐药性当代研究特辑）
Call for Papers: Antimicrobial Resistance（征稿启事：抗菌药物耐药性）
4
How Pooled Procurement Can Expand Access to Novel Antibacterial Therapeutics Globally
集中采购如何在全球范围内扩大新型抗菌疗法的可及性
Jessica Swenson
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 9–15, https://doi.org/10.1093/infdis/jiaf370
5
Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s
妊娠期及产后利福平耐药结核病女性患者使用氯法齐明的药代动力学和安全性：IMPAACT P1026s研究结果
Jennifer A Hughes and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 16–26, https://doi.org/10.1093/infdis/jiaf504
6
Emergence of ST3390: A Novel Apigmented MRSA Clone From the CC5 Lineage
ST3390的出现：源自CC5谱系的一种新型非色素性耐甲氧西林金黄色葡萄球菌克隆
Emily A Felton and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 27–37, https://doi.org/10.1093/infdis/jiaf410
7
Establishing a Practical Approach to Sewer Monitoring for Antimicrobial Resistance Genes and Organisms at Healthcare Facilities
建立医疗机构针对抗菌药物耐药基因和耐药菌的污水监测实用方法
Rachel S Poretsky and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 38–48, https://doi.org/10.1093/infdis/jiaf434
8
Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom
英国近期感染HIV-1人群中非整合酶INSTI耐药相关突变的现实流行率及病毒学结果
Christine Kelly and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 49–58, https://doi.org/10.1093/infdis/jiaf500
9
Detection of Carbapenem-Resistant Bacteria in Skilled Nursing Facility Wastewater
在专业护理机构废水中检测碳青霉烯类耐药细菌
Susanna Lenz and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 59–69, https://doi.org/10.1093/infdis/jiaf534
10
Investigating Azithromycin Activity Against ESBL-Producing Escherichia coli Under Physiologically Relevant Conditions
在生理相关条件下研究阿奇霉素对产超广谱β-内酰胺酶大肠杆菌的活性
Sean Jung and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 70–75, https://doi.org/10.1093/infdis/jiaf480
ID Translational Science Update（传染病转化医学更新）
11
Planning and Analyzing a Low-Biomass Microbiome Study: A Data Analysis Perspective
低生物量微生物组研究的规划与分析：数据分析视角
George I Austin and Tal Korem
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 76–86, https://doi.org/10.1093/infdis/jiae378
Major Articles and Brief Reports（主要论著和简短报告）
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
12
Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli Without Inducing Toxin Production
用于控制产志贺毒素大肠杆菌（STEC）且不诱导毒素产生的烈性噬菌体
Eunshin Cho and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 87–95, https://doi.org/10.1093/infdis/jiaf035
13
Hygromycin A Treatment of Borrelia burgdorferi–Infected Peromyscus leucopus Suggests Potential as a Reservoir-Targeted Antibiotic
对伯氏疏螺旋体感染的白足鼠使用潮霉素A治疗，提示其作为针对储存宿主抗生素的潜在作用
Stephanie S You and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 96–100, https://doi.org/10.1093/infdis/jiaf363
14
Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies
固有杀菌活性低，且其阳性对3期肺炎球菌疫苗成人研究无影响
Weifeng Xu and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 101–111, https://doi.org/10.1093/infdis/jiaf427
15
Population Structure of Escherichia coli Isolated From the Human Bloodstream, Human and Animal Feces, and the Environment in Northern Tanzania
坦桑尼亚北部从人体血液、人和动物粪便以及环境中分离出的大肠杆菌的种群结构
Deng B Madut and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 112–121, https://doi.org/10.1093/infdis/jiaf437
Viral Disease Pathogenesis（病毒性疾病发病机制）
16
Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: A Secondary Analysis of an Animal Challenge Trial
评估流感疫苗保护指标的广度和可靠性：动物挑战试验的二次分析
Yao Lu and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/infdis/jiaf331
17
Assessing the Transmissibility and Outbreak Risk of Measles in the United States, 2024–2030
评估2024 - 2030年美国麻疹的传播性和暴发风险
Subekshya Bidari and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 132–136, https://doi.org/10.1093/infdis/jiaf342
18
Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study
使用生物制剂或小分子药物治疗的自身免疫性疾病患者感染2019冠状病毒病的风险：一项基于人群的队列研究
Eun Mi Song and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 137–147, https://doi.org/10.1093/infdis/jiaf347
19
Leveraging Lyme Disease Surveillance to Simulate Powassan Virus Prevalence
利用莱姆病监测来模拟伯氏疏螺旋体脑炎病毒流行率
James M McCluskey and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 148–152, https://doi.org/10.1093/infdis/jiaf368
20
Human Metapneumovirus–, Respiratory Syncytial Virus–, and Influenza-Associated Pneumonia Hospitalizations in Colorado Adults Aged ≥50 Years, 2016–2023
2016 - 2023年科罗拉多州50岁及以上成年人中与人类偏肺病毒、呼吸道合胞病毒和流感相关的肺炎住院情况
Eric A F Simões and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 153–163, https://doi.org/10.1093/infdis/jiaf381
Malaria Disease Pathogenesis（疟疾发病机制）
21
Digital PCR Reveals High PvDBP1 but not PvEBP/DBP2 and PvRBP2b Copy Number in Plasmodium vivax From Duffy-Negative Individuals in Central Africa
数字PCR显示，在非洲中部杜菲血型阴性个体中，恶性疟原虫的PvDBP1拷贝数高，但PvEBP/DBP2和PvRBP2b拷贝数不高
Bernis Neneyoh Yengo and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 164–172, https://doi.org/10.1093/infdis/jiaf322
22
Elevated Soluble Urokinase-Type Plasminogen Activator Receptor Levels, Organ Dysfunction, and Death in Children Hospitalized With Malaria: Considerations for Use as a Risk Stratification Tool
疟疾住院儿童中可溶性尿激酶型纤溶酶原激活物受体水平升高、器官功能障碍和死亡：作为风险分层工具的考量
Charles Ssuuna and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 173–177, https://doi.org/10.1093/infdis/jiaf327
23
Vaccine-Induced Antibodies to a C-Terminal Plasmodium falciparum Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge
疫苗诱导产生的针对疟原虫环子孢子蛋白C端表位的抗体与对疟疾挑战的保护作用相关
DeAnna J Friedman-Klabanoff and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 178–190, https://doi.org/10.1093/infdis/jiaf391
24
Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial With Controlled Human Malaria Infection
在受控人体疟疾感染的孢子虫疟疾疫苗试验中，与中度和重度不良事件相关的细胞因子
Lauren P Jatt and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 191–196, https://doi.org/10.1093/infdis/jiaf435
Global Health（全球健康）
25
HIV and Syphilis Coinfection in Pregnancy and Adverse Birth Outcomes in Uganda
乌干达妊娠期HIV和梅毒合并感染与不良出生结局
Mehal Churiwal and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 197–205, https://doi.org/10.1093/infdis/jiaf453
26
Antibodies to Tick Salivary Antigens AV422 and Calreticulin in Patients With Spotted Fever Group Rickettsioses and Other Febrile Illnesses in Northern Tanzania
坦桑尼亚北部斑点热群立克次体病及其他发热性疾病患者体内针对蜱唾液抗原AV422和钙网织蛋白的抗体
Ganga S Moorthy and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 206–215, https://doi.org/10.1093/infdis/jiaf506
27
Virological Tools Fail to Properly Identify “Unusual” Hepatitis C Virus Subtypes Resistant to Direct-Acting Antiviral Drugs in The Gambia
病毒学工具未能正确识别冈比亚对直接抗病毒药物耐药的“罕见”丙型肝炎病毒亚型
Erwan Vo-Quang and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages 216–220, https://doi.org/10.1093/infdis/jiaf378
Major Articles and Brief Reports（主要论著和简短报告）
Public Health（公共健康）
28
A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy
评估医疗对策先进研究、开发和监管批准机会的框架：生物医学高级研究与发展管理局（BARDA）新兴传染病战略的组成部分
Richard C White and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e1–e10, https://doi.org/10.1093/infdis/jiaf486
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
29
Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan
日本儿科侵袭性无乳链球菌候选疫苗靶点的流行率及基因组特征
Masashi Kasai and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e11–e21, https://doi.org/10.1093/infdis/jiaf491
30
Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting
载达托霉素纳米载体通过脂质介导的相互作用和靶向作用促进对耐甲氧西林金黄色葡萄球菌的协同杀伤
Jhih-Hang Jiang and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e22–e33, https://doi.org/10.1093/infdis/jiaf492
31
Comparing Respiratory Illness Surveillance Case Definitions to Detect Bordetella pertussis in Children Aged <5 Years With Respiratory Illness in South Africa, 2017–2023
Kate Bishop and others
比较呼吸道疾病监测病例定义以检测2017 - 2023年南非5岁以下呼吸道疾病患儿中的百日咳博德特氏菌
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e34–e43, https://doi.org/10.1093/infdis/jiaf501
32
Insights on Recurrent and Sequential Clostridioides difficile Infections From Genomic Surveillance in Minnesota, USA, 2019–2021
2019 - 2021年美国明尼苏达州基因组监测对复发性及序贯性艰难梭菌感染的见解
Daniel Evans and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e44–e54, https://doi.org/10.1093/infdis/jiaf505
33
Single-Cell Transcriptome Profiling Reveals the Immune Dysregulation Characteristics of Mice Infected With Brucella abortus
单细胞转录组分析揭示感染牛布鲁氏菌小鼠的免疫失调特征
Guangzhi Zhang and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e55–e66, https://doi.org/10.1093/infdis/jiaf522
34
Culture and Adaptation of Pseudomonas aeruginosa During Early Infection in Children With Cystic Fibrosis
囊性纤维化患儿早期感染期间铜绿假单胞菌的培养与适应
Sumitra D Mitra and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e67–e76, https://doi.org/10.1093/infdis/jiaf527
Viral Disease Pathogenesis（病毒性疾病发病机制）
35
Hyperendemicity of Rift Valley Fever in Southwestern Uganda Associated With the Rapidly Evolving Lineage C Viruses
乌干达西南部裂谷热高度流行与快速进化的C谱系病毒相关
Barnabas Bakamutumaho and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e77–e88, https://doi.org/10.1093/infdis/jiaf417
36
Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial
根据衰弱评分比较高剂量与标准剂量流感疫苗对住院和死亡的相对有效性：DANFLU - 1随机试验的事后分析
Caroline Espersen and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e89–e98, https://doi.org/10.1093/infdis/jiaf420
37
Emergence of Two New Lineages of the Cosmopolitan Dengue Virus Serotype 2 in Yunnan, China, 2024
2024年中国云南出现两种新的全球流行性登革热病毒2型谱系
Man Li and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e99–e108, https://doi.org/10.1093/infdis/jiaf422
38
Cerebrospinal Fluid Immune Cell Alterations in Women With Neuropsychiatric Long COVID
神经精神性新冠长期症状女性患者脑脊液免疫细胞改变
Benjamin Orlinick and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e109–e117, https://doi.org/10.1093/infdis/jiaf468
39
The Role of Enoxaparin in Influenza Virus Infections and its Therapeutic Implications
依诺肝素在流感病毒感染中的作用及其治疗意义
Marta Bermejo-Jambrina and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e118–e131, https://doi.org/10.1093/infdis/jiaf470
40
Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada
加拿大多伦多一队列中接受特考韦瑞治疗后猴痘病毒仍排出的情况
Jacklyn R Hurst and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e132–e139, https://doi.org/10.1093/infdis/jiaf471
41
Disentangling Temporal Trends of Clade Ib Monkeypox Virus Transmission in Burundi
厘清布隆迪Ib支系猴痘病毒传播的时间趋势
Shihui Jin and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e140–e144, https://doi.org/10.1093/infdis/jiaf475
42
Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies
利用地理多样性自然感染抗体剖析人乳头瘤病毒谱系特异性衣壳抗原性
Kavita Panwar and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e145–e150, https://doi.org/10.1093/infdis/jiaf502
43
Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation
异基因造血细胞移植后呼吸道病毒感染与肺功能损害
Guang-Shing Cheng and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e151–e163, https://doi.org/10.1093/infdis/jiaf503
Antimicrobial Resistance (AMR)（抗菌药物耐药性）
44
Insights Into Global Antimicrobial Resistance Dynamics Through the Sequencing of Enteric Bacteria From US International Travelers
通过对美国国际旅行者肠道细菌测序洞察全球抗菌药物耐药性动态
Sushmita Sridhar and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e164–e173, https://doi.org/10.1093/infdis/jiaf469
45
The Burden of Surgical Site Infections With Pathogens Presumably Resistant to Perioperative Prophylaxis in Orthopedic Tumor Surgery: Secondary Analysis of the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Trial
骨科肿瘤手术中疑似对围手术期预防用药耐药的手术部位感染负担：肿瘤手术预防性抗生素方案（PARITY）试验的二次分析
Sabine Kuster and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e174–e182, https://doi.org/10.1093/infdis/jiaf513
46
Foreign Combatants Wounded in Ukraine Colonized by Extensively Drug-Resistant Organisms: A Potential Source of Global Dissemination
在乌克兰受伤的外国战斗人员被广泛耐药菌定植：全球传播的潜在来源
Patrick Mc Gann and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e183–e191, https://doi.org/10.1093/infdis/jiaf538
HIV/AIDs（HIV/艾滋病）
47
Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness
针对津巴布韦存在依从性障碍的感染HIV的哺乳期妇女采用长效抗逆转录病毒疗法的临床影响和成本效益建模
Sujata E Tewari and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e192–e202, https://doi.org/10.1093/infdis/jiaf521
48
Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies
PURPOSE 1和2研究中来那卡帕韦、恩曲他滨/丙酚替诺福韦和恩曲他滨/富马酸替诺福韦二吡呋酯的耐药性分析
Stephanie Cox and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e203–e211, https://doi.org/10.1093/infdis/jiaf533
49
Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab
使用来那卡帕韦和广谱中和抗体特罗帕维单抗及津利瑞单抗治疗HIV - 1期间低水平病毒学反弹的耐药性分析
Lisa Selzer and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e212–e220, https://doi.org/10.1093/infdis/jiaf559
50
IL-4 Correlates With Bone Mineral Density in Men, and IL-4 Depletion May Drive Bone Loss in Men With HIV
白细胞介素 - 4与男性骨矿物质密度相关，白细胞介素 - 4耗竭可能导致感染HIV男性骨丢失
Ighovwerha Ofotokun and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e221–e229, https://doi.org/10.1093/infdis/jiaf570
Correspondence（读者来信）
51
External Validation of Pediatric Pneumonia and Bronchiolitis Risk Scores to Predict Mortality in Children Hospitalized in Kenya: A Retrospective Cohort Study
儿科肺炎和毛细支气管炎风险评分在预测肯尼亚住院儿童死亡率方面的外部验证：一项回顾性队列研究
Becky Gordon and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e230–e238, https://doi.org/10.1093/infdis/jiaf377
52
Seroprevalence of Antibodies Against Legionella Species in Northeastern Australian Blood Donors, 2016 and 2023
2016年和2023年澳大利亚东北部献血者中针对军团菌属抗体的血清阳性率
Juniper Lethbridge and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e239–e249, https://doi.org/10.1093/infdis/jiaf407
53
Diagnostic Performance and Kinetics of Hepatitis E Viral RNA and IgM Antibody Test Positivity in a Genotype 1 Outbreak in South Sudan
南苏丹1型基因型戊型肝炎病毒暴发期间戊型肝炎病毒RNA和IgM抗体检测阳性的诊断性能和动力学
Aybüke Koyuncu and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e250–e258, https://doi.org/10.1093/infdis/jiaf436
54
Leptospirosis Prevalence and Risk Factors Among Patients Presenting With Fever to 4 Healthcare Sites in Sub-Saharan Africa and South East Asia: An International Multisite Observational and Nested Case–Control Study
撒哈拉以南非洲和东南亚4个医疗站点发热患者中钩端螺旋体病的流行率和危险因素：一项国际多站点观察性和嵌套病例对照研究
John A Crump and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e259–e270, https://doi.org/10.1093/infdis/jiaf464
55
Refined Transgenic Mouse Models Which Recapitulate the Natural Features of Chronic Wasting Disease With Rapid Prion Disease Onsets
改良转基因小鼠模型可快速引发朊病毒病并重现慢性消耗性疾病的自然特征
Joseph P DeFranco and others
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e271–e276, https://doi.org/10.1093/infdis/jiaf529
Correction（更正）
56
Correction to: Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis
更正：单核细胞和巨噬细胞——严重急性呼吸综合征冠状病毒2的靶点：2019冠状病毒病免疫麻痹的线索
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Page e277, https://doi.org/10.1093/infdis/jiaf622
Editor's Note（编者按）
57
Editor's Note: Bartonella quintana Bacteremia and Overproduction of Interleukin-10: Model of Bacterial Persistence in Homeless People
编者按：五日热巴尔通体菌血症和白细胞介素 - 10过度产生：无家可归者细菌持续存在的模型
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Page e278, https://doi.org/10.1093/infdis/jiaf623
58
Editor's Note: Oral Ivermectin in the Treatment of Body Lice
编者按：口服伊维菌素治疗体虱
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Page e279, https://doi.org/10.1093/infdis/jiaf627
JID 2025 Reviewer Recognition（《传染病杂志》2025年审稿人认证）
59
2025 JID Reviewer Recognition List
2025年《传染病杂志》审稿人认证名单
The Journal of Infectious Diseases, Volume 233, Issue 1, 15 January 2026, Pages e280–e286, https://doi.org/10.1093/infdis/jiag015
The Journal of Infectious Diseases. Volume 233 Issue 2
传染病杂志 233卷 2期
https://academic.oup.com/jid/issue/
Editorials（社论）
1
2025 Content Collections from the IDSA Journals
2025年美国感染病学会（IDSA）期刊内容合集
Roger Bedimo and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 221–222, https://doi.org/10.1093/infdis/jiag041
2
“Fostemsavir: More Than Meets the Eye”
“福替沙韦：不止于表面所见”
Siddharth Kogilwaimath and Netanya S Utay
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 223–226, https://doi.org/10.1093/infdis/jiaf462
3
On-Demand Dosing of HIV Preexposure Prophylaxis for Women: Has Their Time Finally Come?
女性按需服用艾滋病病毒暴露前预防药物：时机是否已到？
Susan P Buchbinder and Peter L Anderson
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 227–229, https://doi.org/10.1093/infdis/jiaf507
Invited Perspective（特邀观点）
4
The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians
感染性疾病领域的范式转变——宿主导向疗法：对下一代传染病医师的影响
Jatin M Vyas and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 230–234, https://doi.org/10.1093/infdis/jiaf497
Invited ID Translational Science Update（特邀传染病转化医学更新）
5
Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy
以色氨酸代谢为靶点，开发结核病生物标志物和宿主导向疗法
Jeffrey M Collins and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 235–243, https://doi.org/10.1093/infdis/jiaf510
6
Clinical Commentary on: Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy
关于“以色氨酸代谢为靶点，开发结核病生物标志物和宿主导向疗法”的临床评论
Joel D Ernst
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 244–246, https://doi.org/10.1093/infdis/jiaf624
Major Articles and Brief Reports（主要论著与简要报告）
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
7
Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV
福替沙韦可降低经治重度HIV感染者体内抗gp120 CD4诱导抗体的水平
Mehdi Benlarbi and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 247–256, https://doi.org/10.1093/infdis/jiaf461
8
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
优化女性按需服用富马酸替诺福韦二吡呋酯/恩曲他滨预防HIV感染的剂量
Nathan Engel and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 257–260, https://doi.org/10.1093/infdis/jiaf459
9
Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy
接受长效肌肉注射卡博特韦加利匹韦林抗逆转录病毒治疗的HIV感染者生殖道分泌物和直肠中的卡博特韦和利匹韦林浓度及HIV-1 RNA抑制情况
Analuz Fernández and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 261–266, https://doi.org/10.1093/infdis/jiaf551
10
Elimination of Human Immunodeficiency Virus Reservoirs Harboring Intact Proviruses
清除携带完整前病毒的HIV储存库
Min Li and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 267–277, https://doi.org/10.1093/infdis/jiaf373
11
Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens
针对细胞来源的隐蔽抗原的病原体疫苗接种
Emily S Clark and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 278–286, https://doi.org/10.1093/infdis/jiaf593
12
NAT2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic–Pharmacokinetic Cohort Study
泰国HIV感染者NAT2基因多态性与抗结核治疗所致肝毒性的关系：一项药物基因组学-药代动力学队列研究的见解
Napon Hiranburana and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 287–297, https://doi.org/10.1093/infdis/jiaf511
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
13
Interplay between Tetanus, Diphtheria, Acellular Pertussis Vaccination in Pregnancy and Infant Pneumococcal Vaccination in Shaping Infant Pneumococcal Vaccine Serotype Carriage
孕期接种破伤风、白喉、无细胞百日咳疫苗与婴儿接种肺炎球菌疫苗对婴儿肺炎球菌疫苗血清型携带的影响
Eline Van den Bosch and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 298–306, https://doi.org/10.1093/infdis/jiaf458
14
Role of Activin A–Mediated KAT8 Expression in Regulating Ferroptosis During Mycobacterium tuberculosis Infection
Activin A介导的KAT8表达在结核分枝杆菌感染中调节铁死亡的作用
Bijewar Ashish Satish and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 307–318, https://doi.org/10.1093/infdis/jiaf482
15
Phospholipid Transporter MlaFEDCB Regulates Klebsiella pneumoniae Virulence by Modulating Fimbriae Synthesis and Stress-adaptive Growth
磷脂转运蛋白MlaFEDCB通过调节菌毛合成和应激适应性生长来调控肺炎克雷伯菌的毒力
Xiaoyu Zhao and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 319–327, https://doi.org/10.1093/infdis/jiaf517
16
Novel KPC-2 Plasmid in a Clinical Salmonella Rissen Selected by Antibiotic Pressure
抗生素压力下临床沙门氏菌里森氏菌中新型KPC-2质粒的出现
María Aznar Fernández and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 328–333, https://doi.org/10.1093/infdis/jiaf536
Viral Disease Pathogenesis（病毒性疾病发病机制）
17
Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains
呼吸道合胞病毒融合蛋白表位特异性抗体对多种呼吸道合胞病毒株的中和活性
Hisao Okabe and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 334–341, https://doi.org/10.1093/infdis/jiaf375
18
Clinical and Environmental Surveillance of Poliovirus Type 2 Outbreak Using a Novel Specific Real-time Quantitative Polymerase Chain Reaction Assay, Israel, 2022–2023
2022-2023年以色列利用新型特异性实时定量聚合酶链反应检测法对2型脊髓灰质炎病毒疫情进行临床和环境监测
Itay Bar-Or and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 342–350, https://doi.org/10.1093/infdis/jiaf387
19
Robust COVID-19 Mortality Risk Assessment: Validation of a Two-Step Algorithm From the National COVID Cohort Collaborative
稳健的COVID-19死亡风险评估：国家COVID队列协作组织的两步算法验证
Bingnan Li and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 351–362, https://doi.org/10.1093/infdis/jiaf393
20
Histone Deacetylase 6 Regulates α-Tubulin to Inhibit the Stimulator of Interferon Genes/NLR Family Pyrin Domain-Containing 3-Mediated Microglial Pyroptosis Induced by Herpes Simplex Virus Type 1 Infection
组蛋白去乙酰化酶6调节α-微管蛋白，抑制1型单纯疱疹病毒感染诱导的干扰素基因刺激因子/NLR家族含吡啶结构域蛋白3介导的小胶质细胞焦亡
Qiongzhen Zeng and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 363–374, https://doi.org/10.1093/infdis/jiaf404
Parasites（寄生虫）
21
Schistosome Infection is Associated With High-Risk Human Papillomavirus Persistence, Together With Altered Cervicovaginal Microbiota
血吸虫感染与高危型人乳头瘤病毒持续感染及宫颈阴道微生物群改变相关
Crispin Mukerebe and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 375–380, https://doi.org/10.1093/infdis/jiaf447
22
The Source-Sink Dynamics of Plasmodium vivax May Undermine Malaria Elimination Efforts in the Amazon: An Epidemiological and Population Genomic Study
恶性疟原虫的源-汇动态可能破坏亚马逊地区疟疾消除工作：一项流行病学和群体基因组学研究
Nathalia Rammé M de Albuquerque and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 381–390, https://doi.org/10.1093/infdis/jiaf457
23
Seasonal Variation and Interspecies Dynamics Among Plasmodium falciparum and ovale Species in Bagamoyo, Tanzania
坦桑尼亚巴加莫约地区恶性疟原虫和卵形疟原虫的季节性变化及种间动态
Kelly Carey-Ewend and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 391–400, https://doi.org/10.1093/infdis/jiaf498
24
Genome Sequencing of Leishmania tropica in Tissues of Moroccan Patients Reveals Microfocal Transmission Underlain by (Pseudo)Clonal and Sexual Reproduction
摩洛哥患者组织中利什曼原虫热带种的基因组测序揭示了（假）克隆和有性繁殖导致的微灶性传播
Othmane Daoui and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 401–410, https://doi.org/10.1093/infdis/jiaf485
25
Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis
顺性别女性服用多西环素暴露后预防药物期间的阴道毛滴虫感染情况
Fredericka Albertina Sesay and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages 411–415, https://doi.org/10.1093/infdis/jiaf519
26
A BEACON for Novel Disease Threats: Leveraging Artificial Intelligence for Informal Event-Based Outbreak Surveillance
应对新型疾病威胁的“灯塔”：利用人工智能进行非正式事件疫情监测
Nahid Bhadelia and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e287–e289, https://doi.org/10.1093/infdis/jiaf642
Major Articles and Brief Reports（主要论著与简要报告）
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
27
Chlamydia trachomatis-specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women
沙眼衣原体特异性T细胞免疫反映南非青少年和年轻女性广泛暴露情况
Rubina Bunjun and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e290–e300, https://doi.org/10.1093/infdis/jiaf595
28
Serum IgG1 and IgG3 Antibodies to Chlamydia trachomatis Pgp3 and Hsp60 in Men of Subfertile Couples
不育夫妇男性体内针对沙眼衣原体Pgp3和Hsp60的血清IgG1和IgG3抗体
Tiina Holster and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e301–e310, https://doi.org/10.1093/infdis/jiaf535
29
Publicly Available Neisseria Gonorrhoeae Genomes Predominantly Represent In Vitro-Derived Nonpiliated Variants
公开可用的淋病奈瑟菌基因组主要代表体外衍生的非菌毛变异体
Iryna Boiko and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e311–e321, https://doi.org/10.1093/infdis/jiaf557
30
Signal Transducers and Activators of Transcription 1 (STAT1), STAT2, and T Cells Mediate Interferon-Dependent Protection Against Neurobrucellosis
信号转导和转录激活因子1（STAT1）、STAT2和T细胞介导干扰素依赖性抗神经布鲁氏菌病的保护作用
Charles R Moley and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e322–e331, https://doi.org/10.1093/infdis/jiaf565
31
[18F]Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring of Acute Staphylococcus aureus Vascular Graft Infection in a Rat Model
[18F]氟脱氧葡萄糖正电子发射断层扫描在诊断和监测大鼠急性金黄色葡萄球菌血管移植物感染中的应用
Emma Faddy and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e332–e341, https://doi.org/10.1093/infdis/jiaf594
32
Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study
健康成年人接种肺炎克雷伯菌四价生物结合疫苗（Kleb4V）的安全性和免疫原性：一项首次人体I/II期随机对照研究
C Alaimo and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e342–e351, https://doi.org/10.1093/infdis/jiaf600
COVID-2019 Disease Pathogenesis（新冠肺炎发病机制）
33
Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022
2022年夏季美国青少年中与新冠长期症状相关症状的流行情况
Deja L Edwards and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e352–e362, https://doi.org/10.1093/infdis/jiaf454
34
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study
血液系统恶性肿瘤患者中COVID-19疫苗的有效性：一项全国性队列研究
Quincy Hofsink and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e363–e372, https://doi.org/10.1093/infdis/jiaf523
35
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
一种由第二代分子夹稳定在融合前构象的严重急性呼吸综合征冠状病毒2型刺突亚单位疫苗在18 - 55岁成年人中的安全性和免疫原性：一项随机、双盲、活性对照、I期试验
Keith J Chappell and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e373–e382, https://doi.org/10.1093/infdis/jiaf568
Viral Disease Pathogenesis（病毒性疾病发病机制）
36
Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine
接种第三剂麻腮风疫苗后腮腺炎抗体反应的持久性
Sun B Sowers and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e383–e391, https://doi.org/10.1093/infdis/jiaf520
37
Immune Responses to BK Virus in Renal Transplant Recipients Receiving Intravenous Immunoglobulin Treatment
接受静脉注射免疫球蛋白治疗的肾移植受者对BK病毒的免疫反应
Kevin D He and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e392–e403, https://doi.org/10.1093/infdis/jiaf525
38
Epstein-Barr Virus Antibody Response Patterns in Endemic and Nonendemic Cases of Nasopharyngeal Carcinoma
鼻咽癌流行区和非流行区病例中EB病毒抗体反应模式
Ilona Argirion and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/infdis/jiaf526
39
Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration
2023 - 2024年西班牙尼塞韦单抗给药季节呼吸道合胞病毒（RSV）的基因组监测和抗原特征分析
María Iglesias-Caballero and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e409–e418, https://doi.org/10.1093/infdis/jiaf530
40
Establishment of a Cynomolgus Macaque Model for Human Adenovirus Type 55–Induced Respiratory Disease
建立食蟹猴模型用于研究人类55型腺病毒引起的呼吸道疾病
Sang Hwan Seo and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e419–e429, https://doi.org/10.1093/infdis/jiaf542
41
Adenovirus 40 and 41 Antibodies Associated With Protection From Infection in a Bangladeshi Birth Cohort
孟加拉国出生队列中与预防腺病毒40型和41型感染相关的抗体
Jennifer Hendrick and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e430–e440, https://doi.org/10.1093/infdis/jiaf558
42
Natural History of Nipah Virus in Hamsters: Strain, Route, and Sex-Associated Variability Characterized Using Large Datasets to Inform Pre-Clinical Study Design
利用大型数据集研究仓鼠中尼帕病毒的自然史：不同毒株、感染途径和性别的变异性，为临床前研究设计提供依据
Katherine A Davies and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e441–e453, https://doi.org/10.1093/infdis/jiaf549
43
Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083
在HPTN 083研究中估算男男性行为者（MSM）和跨性别女性（TGW）中预防有效的长效卡博特韦浓度
Brett Hanscom and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e454–e461, https://doi.org/10.1093/infdis/jiaf561
44
Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young Men
评估年轻男性肛门生殖器部位九价疫苗类型人乳头瘤病毒的一致感染情况
Cara J Broshkevitch and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e462–e470, https://doi.org/10.1093/infdis/jiaf564
Parasites（寄生虫）
45
From Skin to Sequence: Pan-species Detection and Speciation of Leishmania
从皮肤到序列：利什曼原虫的全物种检测与鉴定
Nicholas R Duncan and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e471–e480, https://doi.org/10.1093/infdis/jiaf345
46
A Human Monoclonal Antibody Targeting α-Gal Ameliorates Experimental Cutaneous Leishmaniasis
一种靶向α-半乳糖苷的人单克隆抗体可改善实验性皮肤利什曼病
Hyeseon Cho and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e481–e490, https://doi.org/10.1093/infdis/jiaf350
47
Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023
2023年桑给巴尔和坦桑尼亚的青蒿素部分耐药突变提示区域传播和非洲起源
Sean V Connelly and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e491–e495, https://doi.org/10.1093/infdis/jiaf431
48
A Multivalent Peptide Vaccine Against Malaria, Targeting Plasmodium Circumsporozoite Protein and Mosquito AgTRIO
一种针对疟疾的多价肽疫苗，靶向疟原虫环子孢子蛋白和蚊子AgTRIO
Yu-Min Chuang and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e496–e500, https://doi.org/10.1093/infdis/jiaf432
49
Spontaneous Clearance of Polymerase Chain Reaction–Positive Plasmodium vivax Parasitemia in Northwestern Thailand: An Epidemiological Perspective
泰国西北部聚合酶链反应阳性的恶性疟原虫血症的自发清除：流行病学视角
Pyae Linn Aung and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e501–e509, https://doi.org/10.1093/infdis/jiaf473
50
Gene Editing of a Carcinogenic Liver Fluke Tetraspanin Impairs Parasite Surface Biogenesis and Extracellular Vesicle Uptake by Human Host Cells
对致癌性肝吸虫四跨膜蛋白进行基因编辑，可损害寄生虫表面生物合成以及人宿主细胞对细胞外囊泡的摄取
Sujittra Chaiyadet and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e510–e520, https://doi.org/10.1093/infdis/jiaf466
Antimicrobial Resistance (AMR)（抗菌药物耐药性）
51
Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model
氨苄西林/舒巴坦联合头孢他啶/阿维巴坦治疗产金属β-内酰胺酶的碳青霉烯耐药鲍曼不动杆菌：基于基因组学的机制模型
Bhavatharini Arun and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e521–e533, https://doi.org/10.1093/infdis/jiaf567
52
CRISPR-Cas–associated SCCmec Variants in Methicillin-resistant Staphylococcus aureus Evade Rapid Diagnostic Detection
耐甲氧西林金黄色葡萄球菌中与CRISPR-Cas相关的SCCmec变异体可逃避快速诊断检测
Magdalena Podkowik and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e534–e540, https://doi.org/10.1093/infdis/jiaf575
53
Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa
评估多药耐药铜绿假单胞菌中新型β-内酰胺/β-内酰胺酶抑制剂组合的表型和基因型敏感性检测方法
Clayton W Hall and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e541–e549, https://doi.org/10.1093/infdis/jiaf585
Fungi（真菌）
54
Adrenal Corticosteroids and Increased Intracranial Pressure in Nonimmunocompromised Patients With Cryptococcal Meningitis
非免疫抑制患者隐球菌性脑膜炎的肾上腺皮质类固醇与颅内压升高
John E Bennett and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e550–e552, https://doi.org/10.1093/infdis/jiaf490
55
Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series
非HIV免疫抑制隐球菌性脑膜炎患者感染后炎性综合征的皮质类固醇治疗和长期预后：一项多中心病例系列研究
Yuya Ito and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e553–e560, https://doi.org/10.1093/infdis/jiaf620
56
Cerebral Venous Thrombosis in Previously Healthy Patients with Cryptococcal Meningitis
既往健康患者隐球菌性脑膜炎并发脑静脉血栓形成
Seher H Anjum and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e561–e569, https://doi.org/10.1093/infdis/jiaf653
57
The Gut as a Source of Infection for Fungal Pathogens: Increased Fecal Candida albicans Precedes Onset of Candida Late-Onset Sepsis in Very Preterm Infants
肠道作为真菌病原体感染的来源：极早产儿白色念珠菌粪便含量增加早于迟发性念珠菌脓毒症发作
Rimke R de Kroon and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e570–e581, https://doi.org/10.1093/infdis/jiaf524
Correspondence（读者来信）
58
Accurate Measurement of Viral Clearance in Early-Phase Antiviral Studies in Coronavirus Disease 2019
2019冠状病毒病早期抗病毒研究中病毒清除的准确测量
Phrutsamon Wongnak and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e582–e584, https://doi.org/10.1093/infdis/jiaf442
59
Evaluating Viral Load Sampling Schemes and Swabbing Methods for Optimal Surrogacy
评估病毒载量采样方案和拭子采集方法以实现最佳替代指标
Allyson Mateja and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e585–e586, https://doi.org/10.1093/infdis/jiaf443
60
Effect of 5FU on paracoccidioidomycosis
5-氟尿嘧啶对副球孢子菌病的影响
David A Stevens
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Page e587, https://doi.org/10.1093/infdis/jiaf508
61
Response to D. Stevens Letter
对D. Stevens信件的回复
Nycolas Preite
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Page e588, https://doi.org/10.1093/infdis/jiaf509
62
Evaluating Clinical Impacts of Accessory Genome Elements: Escherichia coli Type III Secretion System 2 in Escherichia coli and Beyond!
评估附属基因组元件的临床影响：大肠杆菌III型分泌系统2在大肠杆菌及其他细菌中的作用！
Abi Manesh and others
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e589–e590, https://doi.org/10.1093/infdis/jiaf515
63
Alarming Prevalence of Gonococcal Ceftriaxone Resistance in Vietnam—Role of Periodic Presumptive Antimicrobials?
越南淋球菌头孢曲松耐药性的惊人流行率——定期假定使用抗菌药物的作用？
Chris Kenyon
The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e591–e592, https://doi.org/10.1093/infdis/jiaf553
The Journal of Infectious Diseases. Volume 233 Issue 3
传染病杂志 233卷 3期
https://academic.oup.com/jid/issue/
Editorial（社论）
1
Mechanistic Insights Into Increased Vulnerability to Respiratory Infections in HIV-Exposed Uninfected Infants
未感染婴儿HIV暴露对呼吸道感染易感性增加的机制研究
Cheryl Cohen and Penny Moore
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 417–419, https://doi.org/10.1093/infdis/jiaf494
Viewpoint（观点）
2
Every Body Has Value: Ending Discriminatory Restrictions on Anatomical Donations
每例身体都有其价值：终止对解剖捐赠的歧视性限制
Sara Gianella and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 420–422, https://doi.org/10.1093/infdis/jiaf413
ID Translational Science Update（传染病转化医学最新进展）
3
Syphilis Transmission: Contagion of Bodies and Words
梅毒传播：身体与言语的双重传播
Maurizio Bifulco and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 423–427, https://doi.org/10.1093/infdis/jiaf576
Major Articles and Brief Reports（主要论著与简要报告）
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Maternal Inflammation Likely Drives Impaired Immune Responses to Respiratory Syncytial Virus in HIV-Exposed Uninfected Infants
母体炎症可能是导致HIV暴露于未感染婴儿对呼吸道合胞病毒免疫应答受损的原因
Christiana Smith and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 428–439, https://doi.org/10.1093/infdis/jiaf493
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
5
Large Reductions in Invasive Pneumococcal Disease and Related Morbidities Among Children in New Zealand After Change From PCV10 to PCV13
新西兰儿童在从PCV10换用PCV13后，侵袭性肺炎球菌病及相关发病率大幅下降
Andrew Anglemyer and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 440–444, https://doi.org/10.1093/infdis/jiaf587
6
Lack of S100A8 Impairs Lung-Protective Immunity Against Streptococcus pneumoniae
缺乏S100A8会损害针对肺炎链球菌的肺部保护性免疫
Lena Ostermann and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 445–457, https://doi.org/10.1093/infdis/jiaf647
7
Microbial Dominance in Diabetic Foot Osteomyelitis Determined With Nanopore Sequencing Techniques Predicts Positive Response to Surgical Intervention
利用纳米孔测序技术确定糖尿病足骨髓炎中的微生物优势种，可预测对手术干预的积极反应
Brian M Schmidt and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 458–464, https://doi.org/10.1093/infdis/jiaf617
8
Characteristics and Antiadhesion Activity of Chicken Single-Chain Fragment Variable Antibodies Against Helicobacter pylori Adhesin A
针对幽门螺杆菌黏附素A的鸡单链抗体片段的特性及其抗黏附活性
Yanan Gong and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 465–474, https://doi.org/10.1093/infdis/jiaf550
9
Bartonella henselae Subverts Host Cell Apoptosis by Linking Intracellular NOD2 Sensing to an AREG/EGFR Autocrine Survival Loop
汉赛巴尔通体通过将细胞内NOD2感知与AREG/EGFR自分泌生存环联系起来，破坏宿主细胞凋亡
Jun He and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 475–484, https://doi.org/10.1093/infdis/jiaf566
Viral Disease Pathogenesis（病毒性疾病发病机制）
10
Influenza-associated Excess Mortality Associated With Influenza B in Hong Kong, 2014–2023
2014 - 2023年香港地区乙型流感相关的超额死亡率
Jessica Y Wong and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 485–492, https://doi.org/10.1093/infdis/jiaf414
11
Disparate Kinetics of Viable Virus Shedding in Immunocompromised Patients: SARS-CoV-2 Versus Influenza Virus—A Prospective Real-World Cohort Study
免疫功能低下患者中存活病毒脱落动力学差异：新冠病毒与流感病毒——一项前瞻性真实世界队列研究
So Yun Lim and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 493–497, https://doi.org/10.1093/infdis/jiaf479
12
Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization
针对I型干扰素的自身抗体是严重急性呼吸综合征冠状病毒2型致命性和住院治疗的显著特征
Rebeca Linhares Abreu Netto and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 498–509, https://doi.org/10.1093/infdis/jiaf514
13
Genetic Landscape of a Cohort of Children With Varicella Zoster Virus Encephalitis, Cerebellitis, and Stroke
水痘带状疱疹病毒脑炎、小脑炎和中风患儿队列的遗传学特征
Franziska Winzig and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 510–520, https://doi.org/10.1093/infdis/jiaf448
14
The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients
可溶性爱泼斯坦-巴尔病毒BZLF1蛋白在实体器官和造血细胞移植受者移植后淋巴增殖性疾病中的诊断价值
Neval Ete Wareham and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 521–527, https://doi.org/10.1093/infdis/jiaf477
15
Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase–Normal Chronic Hepatitis B: A Multicenter Study
丙氨酸氨基转移酶正常的慢性乙型肝炎患者中非侵入性检测隐匿却重要的肝脏病理：一项多中心研究
Xinjie Li and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 528–540, https://doi.org/10.1093/infdis/jiaf554
16
Mesenteric Ischemia and Bacterial Translocation Precipitate the Intoxication Phase of Yellow Fever
肠系膜缺血和细菌移位促使黄热病进入中毒阶段
Mateus V Thomazella and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 541–553, https://doi.org/10.1093/infdis/jiaf483
17
Essential Role of Clathrin and Lipid Rafts in pH-dependent Entry of Chandipura Virus: Independence From Caveolin Pathway
网格蛋白和脂质筏在Chandipura病毒pH依赖性进入过程中的重要作用：独立于小窝蛋白途径
Ritudhwaj Tiwari and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 554–559, https://doi.org/10.1093/infdis/jiaf446
Fungi（真菌）
18
Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness
血培养中含有遗传多样的白色念珠菌菌株群体，这些菌株在棘白菌素耐受性和适应性方面可能存在差异
Giuseppe Fleres and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 560–572, https://doi.org/10.1093/infdis/jiaf495
19
Interferon-gamma Production Defects Characterize Immune Responses in Patients With Chronic Pulmonary Aspergillosis
干扰素-γ产生缺陷是慢性肺曲霉病患者免疫应答的特征
Nico A F Janssen and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 573–582, https://doi.org/10.1093/infdis/jiaf596
20
Tumor Necrosis Factor Receptor–Associated Factor 1 Inhibits Macrophage Killing of Sporothrix schenckii by Enhancing Expression and Activity of Inducible Nitric Oxide Synthase
肿瘤坏死因子受体相关因子1通过增强诱导型一氧化氮合酶的表达和活性，抑制巨噬细胞对申克孢子丝菌的杀伤作用
Congcong He and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 583–593, https://doi.org/10.1093/infdis/jiaf646
Global Health（全球健康）
21
Rifampin Exposure in Pregnant and Nonpregnant Women With Tuberculosis in India
印度结核病孕妇和非孕妇的利福平暴露情况
Prakruti S Rao and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 594–597, https://doi.org/10.1093/infdis/jiaf467
22
Evaluating the Impact of Unadjusted Confounding and Study Design on Estimated Pathogen-attributable Diarrhea Incidence Among Children in the MAL-ED Cohort
评估未调整混杂因素和研究设计对MAL-ED队列中儿童病原体归因腹泻发病率估计的影响
Charlotte R Doran and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 598–606, https://doi.org/10.1093/infdis/jiaf531
23
Defining Severe Shigellosis in the Enterics for Global Health Study: A Comparison of Leading Diarrhea Severity Definitions Among Children With Shigella Diarrhea
全球肠道健康研究中对儿童严重志贺氏菌病的定义：志贺氏菌腹泻儿童中主要腹泻严重程度定义的比较
Olivia Lang Schultes and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages 607–617, https://doi.org/10.1093/infdis/jiaf630
Editorial（社论）
24
Evidence for Neuroinvasive Lassa Virus Infection in Pediatric Patients: Initial Findings and Implications
儿科患者神经侵袭性拉沙病毒感染的证据：初步发现及启示
Andrew P Platt and Daniel S Chertow
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e593–e595, https://doi.org/10.1093/infdis/jiaf548
Perspectives（展望）
25
The Emerging Role of Immunothrombosis in the Control and Pathogenesis of Mycobacterium tuberculosis
免疫血栓形成在结核分枝杆菌控制和发病机制中的新兴作用
Seán Donohue and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e596–e599, https://doi.org/10.1093/infdis/jiaf415
ID Translational Science Update（传染病转化医学最新进展）
26
Whole-Exome Sequencing for the Identification of Genetic Factors Implicated in Severe Bacterial Infections: A Systematic Review
全外显子组测序用于鉴定与严重细菌感染相关的遗传因素：一项系统综述
Morgane Gélin and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e600–e610, https://doi.org/10.1093/infdis/jiag006
Major Articles and Brief Reports（主要论著与简要报告）
Viral Disease Pathogenesis（病毒性疾病发病机制）
27
Presence of Lassa Virus RNA in Cerebrospinal Fluid Indicating Neuroinvasive Lassa Fever in Pediatric Patients From Edo State, Nigeria
尼日利亚埃多州儿科患者脑脊液中存在拉沙病毒RNA，表明存在神经侵袭性拉沙热
Hannah Caroline Sophie Müller and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e611–e620, https://doi.org/10.1093/infdis/jiaf547
28
Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B
抗-HBs免疫复合物水平：乙型肝炎e抗原阴性慢性乙型肝炎患者核苷（酸）类似物停药后肝炎发作的新型标志物
S J Hume and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e621–e629, https://doi.org/10.1093/infdis/jiaf569
29
Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B
慢性乙型肝炎患者核苷（酸）类似物停药时口腔微生物组多样性的重要性
Mahin Ghorbani and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e630–e640, https://doi.org/10.1093/infdis/jiaf591
30
A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults
一项评估健康成年人接种麻疹载体基孔肯雅病毒疫苗（MV-CHIK）的安全性、免疫原性和剂量的1期双盲试验
Patricia Winokur and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e641–e645, https://doi.org/10.1093/infdis/jiaf571
31
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples
免疫相关因素的检验阴性设计近似于传统的暴露近端设计，但所需血液样本数量要少得多
Dean Follmann and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e646–e650, https://doi.org/10.1093/infdis/jiaf572
32
Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus
人偏肺病毒和呼吸道合胞病毒感染住院成人患者的医疗资源利用情况和疾病预后比较
Emily Rayens and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e651–e661, https://doi.org/10.1093/infdis/jiaf597
33
Avian Influenza Virus A(H5N1) Genotype D1.1 Is Better Adapted to Human Nasal and Airway Organoids Than Genotype B3.13
禽流感病毒A(H5N1) D1.1基因型比B3.13基因型更适应人体鼻腔和气道类器官
Xiaojuan Zhang and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e662–e666, https://doi.org/10.1093/infdis/jiaf598
34
The Impact of Corticosteroid Therapy on Patients With West Nile Virus: A Retrospective Cohort Study
皮质类固醇治疗对西尼罗河病毒患者的影响：一项回顾性队列研究
Itamar Poran and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e667–e673, https://doi.org/10.1093/infdis/jiaf601
35
Serological Survey in African Nonhuman Primate Species in Cameroon and the Democratic Republic of the Congo Reveals Low Overall Seroprevalence to Mpox Virus
对喀麦隆和刚果民主共和国非洲非人灵长类物种的血清学调查显示，猴痘病毒总体血清阳性率较低
Neraide Biai and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e674–e686, https://doi.org/10.1093/infdis/jiaf602
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
36
Manufacture of Clostridioides difficile Spores for Experimental Infection of Human Volunteers
用于人体志愿者实验性感染的艰难梭菌孢子制备
Annefleur D O Hensen and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e687–e695, https://doi.org/10.1093/infdis/jiaf612
37
Digital Anorectal Examination to Self-detect Primary Syphilis: A Prospective Cohort Study
数字肛门直肠检查用于自我检测原发性梅毒：一项前瞻性队列研究
Julien Tran and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e696–e705, https://doi.org/10.1093/infdis/jiaf628
38
Higher Promoter Methylation of the Ubiquitin-Associated and SH3 Domain Containing A (UBASH3A) Gene Is Associated With T-Lymphocyte Ontogeny and Reduced Susceptibility to Early-Onset Sepsis
泛素相关和SH3结构域含A（UBASH3A）基因启动子高甲基化与T淋巴细胞发生及早发性脓毒症易感性降低相关
Ziyi Wang and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e706–e711, https://doi.org/10.1093/infdis/jiaf636
39
Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse
小鼠肺鸟分枝杆菌感染序贯单一疗法的疗效
Ruth A Howe and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e712–e720, https://doi.org/10.1093/infdis/jiaf640
40
The Landscape and Regulatory Determinants of A-to-I RNA Editing in Escherichia coli and Pseudomonas aeruginosa Isolated From Patients With Urinary Tract and Ear Infections
从尿路感染和耳部感染患者中分离出的大肠杆菌和铜绿假单胞菌中A-to-I RNA编码的格局及调控决定因素
Eyal Elias and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e721–e730, https://doi.org/10.1093/infdis/jiaf645
Parasites（寄生虫）
41
Efficacy of Praziquantel for Treatment of Plasmodium falciparum Infection in Asymptomatic Gabonese Adults: A Double-Blind Placebo-Controlled Randomized Trial
双盲安慰剂对照随机试验评估吡喹酮治疗加蓬无症状成人恶性疟原虫感染的疗效
Johannes Mischlinger and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e731–e739, https://doi.org/10.1093/infdis/jiaf544
42
Chronic Malaria Is Associated With Trauma-related Splenic Rupture Requiring Splenectomy
慢性疟疾与创伤性脾破裂相关，需行脾切除术
Putu A I Shanti and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e740–e744, https://doi.org/10.1093/infdis/jiaf629
43
Extreme Genetic Diversity and Signatures of Balancing Selection in Plasmodium vivax Blood-Stage Antigens
间日疟原虫血液阶段抗原具有极高的遗传多样性和平衡选择的特征
Alison Paolo N Bareng and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e745–e755, https://doi.org/10.1093/infdis/jiaf539
44
How Duffy Blood Group (FY) Polymorphism and Age Modulate Vivax Malaria Risk at the Community Level: A Population-based Retrospective Cohort Study in the Amazon
社区层面杜菲血型（FY）多态性和年龄如何调节间日疟风险：亚马逊地区一项基于人群的回顾性队列研究
Carlos A Prete and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e756–e765, https://doi.org/10.1093/infdis/jiaf562
45
New Viability Assays for Acanthamoeba castellanii Trophozoites and Cysts Allow Rapid Assessment of Drug Activity
卡氏棘阿米巴滋养体和包囊新的活性检测方法可快速评估药物活性
Carrie A Flynn and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e766–e776, https://doi.org/10.1093/infdis/jiaf599
Global Health（全球健康）
46
Stunting Increases Influenza Virus Shedding Duration in Preschool/School-Aged Children
发育迟缓会增加学龄前/学龄儿童流感病毒脱落持续时间
Mia Q Zhu and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e777–e781, https://doi.org/10.1093/infdis/jiaf641
47
False-positive Malaria Rapid Diagnostic Tests are Prevalent Among Children Under 5 Years of Age in Uganda
乌干达5岁以下儿童疟疾快速诊断试验假阳性率较高
Caitlin A Cassidy and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e782–e790, https://doi.org/10.1093/infdis/jiaf604
48
Comparative Analysis of Flight Volume Effects on COVID-19 and Influenza Transmission Across Variable Control Intensities, 2019–2024
2019 - 2024年不同防控强度下航班量对新冠肺炎和流感传播影响的比较分析
Yanfang Xu and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e791–e801, https://doi.org/10.1093/infdis/jiaf545
49
High Seropositivity to rK39 and Capture of Leishmania-Infected Sand Flies in Bihar and Jharkhand Emphasize the Need for Post-Elimination Surveillance of Visceral Leishmaniasis in India
比哈尔邦和贾坎德邦rK39血清阳性率高且捕获到感染利什曼原虫的白蛉，强调印度内脏利什曼病消除后需加强监测
Eva Iniguez and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e802–e811, https://doi.org/10.1093/infdis/jiaf543
Microbiome（微生物组）
50
The Gut Microbiome and Butyrate Differentiate Clostridioides difficile Colonization and Infection in Children
肠道微生物组和丁酸盐可区分儿童艰难梭菌定植和感染
Maribeth R Nicholson and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e812–e822, https://doi.org/10.1093/infdis/jiaf631
51
Gut Microbiota Predicts the Risk of Future COVID-19 Hospitalization and Mortality: Insights From the Population-Based HELIUS Study
肠道微生物群可预测未来新冠肺炎住院和死亡风险：来自基于人群的HELIUS研究的见解
Robert F J Kullberg and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e823–e827, https://doi.org/10.1093/infdis/jiaf541
52
Douching Is Associated With Dysregulated Rectal Mucosal Immunity in Sexual Minority Men
灌洗与性少数男性直肠黏膜免疫失调相关
Courtney A Broedlow and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e828–e838, https://doi.org/10.1093/infdis/jiaf577
Correspondence（读者来信）
53
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 in Long-Term Care
13价肺炎球菌结合疫苗对长期护理机构中≥65岁医疗保险受益人肺炎住院的预防效果
Wenwen Zhao and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Page e839, https://doi.org/10.1093/infdis/jiaf581
54
Letter to the Editor in Response to Zhao et al
致编辑的信（回应赵等人）
Lindsay Zielinski and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e840–e841, https://doi.org/10.1093/infdis/jiaf582
55
Fishborne Trematodiases in the United States: A Blind Spot in U.S. Emerging Infectious Disease Preparedness
美国鱼源性吸虫病：美国新兴传染病防范中的盲点
Nathkapach K Rattanapitoon and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e842–e843, https://doi.org/10.1093/infdis/jiaf588
56
Comment on “A Review of Aedes aegypti Control in Peru: Approaches and Lessons Learned”
对“秘鲁伊蚊控制回顾：方法与经验教训”的评论
Carmen Thompson Perea and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e844–e845, https://doi.org/10.1093/infdis/jiaf589
57
Balancing Pharmacokinetic Targets and Lymphocyte Declines with Once-Monthly Oral Islatravir for PrEP
平衡药代动力学目标和淋巴细胞减少情况，每月一次口服艾斯拉特韦用于暴露前预防
Anxin Wen
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e846–e847, https://doi.org/10.1093/infdis/jiaf618
58
Polio-Free, Not Risk-Free: Wastewater as Early Warning
无脊髓灰质炎，但并非无风险：废水作为早期预警
Francesco Branda and others
The Journal of Infectious Diseases, Volume 233, Issue 3, 15 March 2026, Pages e848–e849, https://doi.org/10.1093/infdis/jiaf643
The Journal of Infectious Diseases. Volume 233 Issue Supplement_1
传染病杂志 233卷 增刊1期
https://academic.oup.com/jid/issue/233/Supplement_1
SUPPLEMENT（增刊）
Molecular Epidemiology of β-Lactam Resistance in Gram-negative Bacteria in China
中国革兰氏阴性菌β-内酰胺酶类抗生素耐药性的分子流行病学
Supplement Articles（增补论著）
1
Aztreonam-Avibactam Resistance Due to Synergistic Interplay of ampC-Related Mutations in Carbapenem-Resistant Enterobacter spp
碳青霉烯耐药肠杆菌属中因ampC相关突变的协同作用导致的氨曲南-阿维巴坦耐药
Yang Zeng and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S1–S9, https://doi.org/10.1093/infdis/jiaf384
2
Molecular Mechanisms of β-Lactam Resistance and Its Contribution to Multidrug Resistance in Helicobacter pylori
幽门螺杆菌β-内酰胺酶类抗生素耐药的分子机制及其对多重耐药的影响
Jun Zhou and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S10–S20, https://doi.org/10.1093/infdis/jiaf385
3
Molecular Epidemiology and Persistence of Multidrug-Resistant Acinetobacter baumannii in Zhejiang, China (2015–2020): Insights Into Resistance, Virulence, and Transmission Dynamics
2015 - 2020年中国浙江地区多重耐药鲍曼不动杆菌的分子流行病学及持久性：对耐药性、毒力和传播动态的见解
Yisha Zhang and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S21–S30, https://doi.org/10.1093/infdis/jiaf425
4
Clinical Outcomes in Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae Infection: A Cohort Study
高毒力碳青霉烯耐药肺炎克雷伯菌感染的临床预后：一项队列研究
Ya Hu and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S31–S37, https://doi.org/10.1093/infdis/jiaf460
5
Reduced Susceptibility to Cefepime–Taniborbactam in Carbapenem-Resistant Klebsiella pneumoniae Attributed to Penicillin-Binding Protein 3 Modifications
碳青霉烯耐药肺炎克雷伯菌中因青霉素结合蛋白3修饰导致对头孢吡肟-他尼硼巴坦敏感性降低
Baofang Zhang and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S38–S46, https://doi.org/10.1093/infdis/jiaf463
6
Isolation of Lytic Bacteriophages Against Carbapenem-Resistant Klebsiella pneumoniae of Capsular Type KL64 From Water Collected at Multiple Sites Across China
从中国多个地点采集的水样中分离出针对荚膜型KL64碳青霉烯耐药肺炎克雷伯菌的溶菌性噬菌体
Juan Li and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S47–S55, https://doi.org/10.1093/infdis/jiaf607
7
Clinical and Molecular Characteristics of Carbapenem-Resistant Klebsiella pneumoniae Causing Bloodstream Infection in a Chinese Teaching Hospital
中国某教学医院引起血流感染的碳青霉烯耐药肺炎克雷伯菌的临床和分子特征
Quanfeng Liao and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S56–S63, https://doi.org/10.1093/infdis/jiaf613
8
OmpK35 and OmpK36 Deficiencies Driving High-level Carbapenem Resistance in ST11 Klebsiella Pneumoniae
OmpK35和OmpK36缺失导致ST11型肺炎克雷伯菌高水平碳青霉烯耐药
Jiayuan Qin and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S64–S71, https://doi.org/10.1093/infdis/jiaf621
9
Carbapenem-Resistant Klebsiella pneumoniae of Sequence Type 11: A Scoping Review
序列型11的碳青霉烯耐药肺炎克雷伯菌：一项范围综述
Yongqiang Yang and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S72–S80, https://doi.org/10.1093/infdis/jiaf635
10
Emergence of Carbapenem-Resistant Escherichia coli Coharboring blaCTX-M-199 and Penicillin-Binding Protein 3 Insertion Conferring Increased Aztreonam/Avibactam Resistance in South China
中国南方出现携带blaCTX-M-199且青霉素结合蛋白3插入导致氨曲南/阿维巴坦耐药性增强的碳青霉烯耐药大肠埃希菌
Jiong Wang and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S81–S91, https://doi.org/10.1093/infdis/jiag025
11
Challenges and Strategies in Managing β-Lactam–Resistant Pseudomonas aeruginosa in China
中国应对β-内酰胺酶类抗生素耐药的铜绿假单胞菌所面临的挑战和策略
Yue Li and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S92–S103, https://doi.org/10.1093/infdis/jiag033
12
New Delhi Metallo-β-Lactamase Carbapenem-Resistant Klebsiella pneumoniae in Neonates: A Genome-Based Surveillance Study
新生儿中新德里金属β-内酰胺酶碳青霉烯耐药肺炎克雷伯菌：一项基于基因组的监测研究
Liting Liang and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S104–S112, https://doi.org/10.1093/infdis/jiag034
13
Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024
2015 - 2024年中国碳青霉烯耐药革兰氏阴性菌的趋势：一项监测研究
Yan Guo and others
The Journal of Infectious Diseases, Volume 233, Issue Supplement_1, 15 March 2026, Pages S113–S117, https://doi.org/10.1093/infdis/jiag083
The Journal of Infectious Diseases. Volume 233 Issue 4
传染病杂志 233卷 4期
https://academic.oup.com/jid/issue/
Editorial（社论）
1
The Editors' Update: JID Continues to Evolve
社论更新：《传染病杂志》持续发展
Cornelius J (Neil) Clancy and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 619–620, https://doi.org/10.1093/infdis/jiag159
2
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：提高传染病研究的透明度
Jean-Jacques Parienti and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Page 621, https://doi.org/10.1093/infdis/jiag134
3
Dissecting the Impact of the Gut Microbiome on HIV Reservoir Dynamics
剖析肠道微生物组对HIV储存库动态的影响
Christopher M Basting and Nichole R Klatt
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/infdis/jiaf560
Viewpoint（观点）
4
Doxycycline Post-exposure Prophylaxis and Off-target Antimicrobial Resistance: Potential Amplification Within Sexual Networks
多西环素暴露后预防用药与非靶向抗菌药物耐药性：性网络内潜在的耐药性放大
Manon Roberts and Peter Davis
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 625–627, https://doi.org/10.1093/infdis/jiaf439
5
Clearing the Air: Rethinking Airway Infection With CFTR Modulators
清除迷雾：重新思考囊性纤维化跨膜转导调节因子调节剂治疗下的气道感染
Edith T Zemanick and Ranjani Somayaji
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 628–630, https://doi.org/10.1093/infdis/jiaf625
Invited ID Translational Science Update（特邀传染病转化医学更新）
6
Microbiota, Mucus, and Modulators: Cystic Fibrosis Infection Pathogenesis in the Cystic Fibrosis Transmembrane Conductance Regulator Modulator Era
微生物群、黏液与调节剂：囊性纤维化跨膜转导调节因子调节剂时代囊性纤维化感染的发病机制
Christina S Thornton and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 631–639, https://doi.org/10.1093/infdis/jiaf626
Major Articles and Brief Reports（论著与简报）
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
7
HIV Reservoir Dynamics and Bacteriome Composition Along the Gut Axis
肠道轴上HIV储存库动态与细菌群组成
Mattia Trunfio and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 640–651, https://doi.org/10.1093/infdis/jiaf546
8
Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models
急性和慢性人类免疫缺陷病毒感染中线粒体DNA片段动态：来自人类和非人类灵长类动物模型的见解
Jing Sun and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 652–663, https://doi.org/10.1093/infdis/jiag014
9
Multiancestry Genome-Wide Association Study Identifies Variants in a Zinc Finger Gene Cluster as Novel Regulators of HIV Control
多祖先全基因组关联研究确定锌指基因簇中的变异体作为HIV控制的新型调节因子
Abraham Awada and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 664–673, https://doi.org/10.1093/infdis/jiag072
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
10
Respiratory Syncytial Virus–Mediated Gas6/Axl Axis Induces Hyporesponsive Macrophages to Promote Pneumococcal Proliferation in the Nasopharynx
呼吸道合胞病毒介导的Gas6/Axl轴诱导巨噬细胞低反应性以促进鼻咽部肺炎链球菌增殖
Saki Ishikawa and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 674–684, https://doi.org/10.1093/infdis/jiag004
11
Variable Staphylothrombin Activity in Staphylococcus aureus Bloodstream Infections
金黄色葡萄球菌血流感染中可变的葡萄球菌凝血酶活性
Gregory L Damhorst and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 685–695, https://doi.org/10.1093/infdis/jiag012
12
TLR4–MyD88–NF-κB Signaling in the Airway Epithelium Promotes Acinetobacter baumannii Clearance
气道上皮细胞中的TLR4-MyD88-NF-κB信号通路促进鲍曼不动杆菌的清除
Jisun Kim and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 696–705, https://doi.org/10.1093/infdis/jiag061
Viral Disease Pathogenesis（病毒性疾病发病机制）
13
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study
先天性巨细胞病毒感染接受治疗的早产儿更昔洛韦剂量：一项前瞻性药代动力学研究结果
Edward P Acosta and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 706–713, https://doi.org/10.1093/infdis/jiaf528
14
National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis
2020年1月至2023年12月国家及州级SARS-CoV-2免疫趋势：一项数学建模分析
Fayette Klaassen and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 714–724, https://doi.org/10.1093/infdis/jiaf532
15
Risk- and Response-Adapted Treatment in Pediatric Epstein-Barr Virus–Associated Hemophagocytic Lymphohistiocytosis
儿童EB病毒相关噬血细胞性淋巴组织细胞增生症的风险和反应适应性治疗
Jing Miao and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 725–734, https://doi.org/10.1093/infdis/jiaf556
16
IPVS Consensus Statement on The Natural History of Cervical Human Papillomavirus Infection
国际乳头瘤病毒学会关于宫颈人乳头瘤病毒感染自然史的共识声明
Marc D Ryser and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 735–744, https://doi.org/10.1093/infdis/jiaf574
17
Long Non-Coding RNA NEAT1 Inhibits Enterovirus 71 Replication by Enhancing IFN-β Transcription Through DDX60 Signaling: Pathological Insights and Clinical Implications
长链非编码RNA NEAT1通过DDX60信号增强IFN-β转录抑制肠道病毒71型复制：病理学见解与临床意义
Dong Li and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 745–757, https://doi.org/10.1093/infdis/jiaf578
18
A Threshold in Anti–EBNA-1 Antibody Titers Distinguishes Salivary EBV Shedders From Nonshedders
抗EBNA-1抗体滴度的阈值可区分唾液EB病毒脱落者与非脱落者
João Vitor Mahler and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 758–762, https://doi.org/10.1093/infdis/jiag010
Tuberculosis（结核病）
19
Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa
南非西开普省使用受访者驱动抽样法研究吸食非法毒品者中结核病的患病率
Samantha Malatesta and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 763–772, https://doi.org/10.1093/infdis/jiaf481
20
Childhood Tuberculosis and Risk of Frailty in Later Life: Evidence From a Nationally Representative Study in Brazil
巴西一项全国代表性研究显示儿童期结核病与晚年衰弱风险的关系
Evelyn Lepka de Lima and Márlon Juliano Romero Aliberti
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 773–776, https://doi.org/10.1093/infdis/jiaf563
21
A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis
单价SMAC模拟物作为结核病潜在宿主导向疗法
Jiahong Ji and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 777–786, https://doi.org/10.1093/infdis/jiag031
22
Cerebrospinal Fluid Hypo-inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis
脑脊液低炎症反应是HIV相关结核性脑膜炎死亡的原因
Anna L Wilt and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages 787–798, https://doi.org/10.1093/infdis/jiag032
Editorial（社论）
23
Guiding Lines: Practical and Accessible Approaches for Analyzing Serological Data for Infectious Disease Surveillance
指导方针：用于传染病监测的血清学数据分析的实用且易获取的方法
Laura C Steinhardt
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e850–e852, https://doi.org/10.1093/infdis/jiag054
Perspectives（观点）
24
Commensal Bacteria: An Under-recognized Cause of Pneumonia
共生菌：一种被忽视的肺炎病因
Daniel M Musher and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e853–e856, https://doi.org/10.1093/infdis/jiag053
25
The Role of Antiviral Treatment of Influenza in Reducing Hospitalizations and Other Severe Outcomes: A Need for More Evidence
抗病毒治疗流感在减少住院和其他严重结局方面的作用：需要更多证据
Mark W Tenforde and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e857–e861, https://doi.org/10.1093/infdis/jiaf573
Major Articles and Brief Reports（论著与简报）
Special Report（专题报告）
26
Whose Line Is it Anyway? Defining Seropositivity Cutoffs for Infectious Disease Surveillance
究竟以谁为准？确定传染病监测血清阳性临界值
Michael T White and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e862–e871, https://doi.org/10.1093/infdis/jiaf537
Parasites（寄生虫）
27
Quantifying the Role of Importation on Sustained Malaria Transmission in a Low-to-Moderate Burden Region of Southwest Uganda
量化输入在维持乌干达西南部低至中度负担地区疟疾持续传播中的作用
Adrienne Epstein and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e872–e881, https://doi.org/10.1093/infdis/jiag008
28
Antibody-Dependent Neutrophil Phagocytosis of Plasmodium falciparum–Infected Erythrocytes Is Mediated by FcγRIIa
抗体依赖的中性粒细胞吞噬恶性疟原虫感染的红细胞由FcγRIIa介导
Maria Saeed and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e882–e890, https://doi.org/10.1093/infdis/jiag071
29
Comparison of CD4 T-Cell Response in Plasmodium falciparum and vivax Malaria
恶性疟原虫和间日疟原虫疟疾中CD4 T细胞反应的比较
Mayimuna Nalubega and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e891–e901, https://doi.org/10.1093/infdis/jiag115
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
30
Persistent Increased Plasmacytoid Dendritic Cells and Inflammation in People With HIV Years After Tuberculosis
结核病治愈数年后，HIV感染者体内浆细胞样树突状细胞持续增多且炎症反应持续存在
Maureen Ward and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e902–e912, https://doi.org/10.1093/infdis/jiaf499
31
Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy
急性HIV感染期及立即接受抗逆转录病毒治疗后出现的神经轴突损伤
Phillip Chan and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e913–e922, https://doi.org/10.1093/infdis/jiaf583
32
Weekly Oral Prophylaxis With MK-8527 Protects Rhesus Macaques From Intrarectal Challenge With Simian–Human Immunodeficiency Virus
每周口服MK-8527进行预防可保护恒河猴免受猴-人免疫缺陷病毒的直肠攻击
Tracy L Diamond and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e923–e931, https://doi.org/10.1093/infdis/jiaf610
33
Partial Post-exposure Protection by Topical Inserts Containing Tenofovir Alafenamide Fumarate/Elvitegravir in a Macaque Model of Rectal Simian HIV (SHIV) Infection
在猕猴直肠猴免疫缺陷病毒（SHIV）感染模型中，含富马酸替诺福韦艾拉酚胺/埃维替韦的局部插入物提供部分暴露后保护
Natalia Makarova and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e932–e936, https://doi.org/10.1093/infdis/jiaf611
34
Human Immunodeficiency Virus–Associated Proteomic Signature of Myocardial Fibrosis and Incident Heart Failure
人类免疫缺陷病毒相关心肌纤维化和偶发心力衰竭的蛋白质组学特征
Tess E Peterson and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e937–e947, https://doi.org/10.1093/infdis/jiag013
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
35
Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?
通过去除伪装抗体治疗铜绿假单胞菌感染：常见多糖抗原是否是一个因素？
Joshua N Monteith and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e948–e956, https://doi.org/10.1093/infdis/jiag002
36
High Prevalence and Genotypic Diversity of Persistent Chlamydia Trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities
南非少女和年轻女性中持续性沙眼衣原体感染的患病率高且基因型多样：两个城市的对比情况
Smritee Dabee and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e957–e962, https://doi.org/10.1093/infdis/jiag023
37
The Effect of Pertussis Vaccination During Pregnancy on the Binding Epitopes and Avidity of Anti–Pertussis Toxin Immunoglobulin G Antibodies in Infants and Their Mothers
孕期接种百日咳疫苗对婴儿及其母亲体内抗百日咳毒素免疫球蛋白G抗体的结合表位和亲和力的影响
Aapo Knuutila and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e963–e972, https://doi.org/10.1093/infdis/jiag048
Tuberculosis（结核病）
38
Accuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border
表型1G试验检测美国-墨西哥边境痰液中结核分枝杆菌及耐药性的准确性
Mia Aguirre and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e973–e980, https://doi.org/10.1093/infdis/jiaf638
39
Mycobacterium tuberculosis–Specific CFP-10/ESAT-6 CD4 and CD8 T-Cell Non-IFN-γ+ Responses Are Common in Young Kenyan Children Despite Low Reported Tuberculosis Exposure
尽管报告的结核病暴露率较低，但肯尼亚幼儿中仍普遍存在结核分枝杆菌特异性CFP-10/ESAT-6 CD4和CD8 T细胞非γ干扰素阳性反应
Sylvia M LaCourse and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e981–e989, https://doi.org/10.1093/infdis/jiag039
40
Modeling the Impact of Case Finding for Tuberculosis: The Role of Infection Dynamics
结核病病例发现的影响建模：感染动态的作用
Theresa S Ryckman and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e990–e998, https://doi.org/10.1093/infdis/jiag050
41
Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
2R2随机对照试验中用于结核病预防治疗的标准剂量和高剂量利福平的群体药代动力学建模
Fajri Gafar and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e999–e1010, https://doi.org/10.1093/infdis/jiag052
Viruses（病毒）
42
Improved Immune Response Against Influenza A Viruses With Receipt of a Recombinant Influenza Vaccine in Healthcare Personnel With Prior Low Antibody Response to Egg-Based Influenza Vaccines, Israel, 2019–2020
2019-2020年，以色列既往对基于鸡蛋的流感疫苗抗体反应低的医护人员接种重组流感疫苗后，对甲型流感病毒的免疫反应有所改善
Kelsey M Sumner and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1011–e1021, https://doi.org/10.1093/infdis/jiaf605
43
Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial
老年人连续接种强化流感疫苗后抗神经氨酸酶抗体反应：一项随机对照试验
Pavithra Daulagala and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1022–e1030, https://doi.org/10.1093/infdis/jiaf616
44
The Pandemic Respiratory Virus Epidemiological Surveillance Trial-A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking
大流行性呼吸道病毒流行病学监测试验——嵌入FluTracking的呼吸道病毒自我拭子监测系统
Camille Esneau and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1031–e1039, https://doi.org/10.1093/infdis/jiaf632
45
Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection
先天性巨细胞病毒感染患儿体内更昔洛韦三磷酸的细胞内浓度
Brent Lindquist-Kleissler and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1040–e1045, https://doi.org/10.1093/infdis/jiaf633
46
Hepatitis E Virus Infection in Patients With Chronic Liver Diseases: A Latin American Multicenter Study
拉丁美洲多中心研究：慢性肝病患者中的戊型肝炎病毒感染情况
Anabella Clara Fantilli and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1046–e1055, https://doi.org/10.1093/infdis/jiaf615
47
In Vivo Risk Assessment of Yellow Fever Virus Transmission Through Breastfeeding, and Mechanistic Insights
母乳喂养传播黄热病病毒的体内风险评估及机制研究
Jeanne Pascard and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1056–e1068, https://doi.org/10.1093/infdis/jiaf637
Letters to the Editor（致编辑的信）
48
Re: Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis
回复：估算耐药结核病新治疗方案对早期传播的抑制作用
Tom A Yates and David A Barr
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1069–e1070, https://doi.org/10.1093/infdis/jiaf655
49
Reply to Yates and Barr
回复耶茨和巴尔
Ruvandhi R Nathavitharana and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1071–e1072, https://doi.org/10.1093/infdis/jiaf656
50
How “Enhanced” Are Enhanced Influenza Vaccines for Neuraminidase? Antigen Content and Baseline Immunity Revisited
强化流感疫苗对神经氨酸酶的“强化”程度如何？重新审视抗原含量和基线免疫力
Xiaowei Zhang
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1073–e1074, https://doi.org/10.1093/infdis/jiag042
51
Response to Letter to the Editor Regarding the Immunogenicity of Enhanced Influenza Vaccines in Inducing Neuraminidase Inhibition Antibodies
回复致编辑的关于“强化流感疫苗诱导神经氨酸酶抑制抗体免疫原性”的信
Pavithra Daulagala and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1075–e1076, https://doi.org/10.1093/infdis/jiag043
52
Comment on B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients
关于“B细胞亚群表征预测实体器官移植受者对SARS-CoV-2疫苗反应”的评论
Pınar Belviranlı Keskin
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Page e1077, https://doi.org/10.1093/infdis/jiag055
53
Response to Dr Belviranli Keskin's Comments
回复贝尔维兰利·凯斯金的评论
James J Knox and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Page e1078, https://doi.org/10.1093/infdis/jiag056
54
Beyond Antibodies: Influenza Vaccine Induced T-Cell Response in Hematological Malignancy— Commentary on Insights From Hall et al
超越抗体：流感疫苗在血液系统恶性肿瘤患者中诱导的T细胞反应——对霍尔等人见解的评论
Katja M Sauer and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1079–e1080, https://doi.org/10.1093/infdis/jiag079
55
Advancing Understanding of Viral Interference: Insights From Rhinovirus–SARS-CoV-2 Cross-protection and Immunologic Perspectives
加深对病毒干扰的理解：来自鼻病毒-SARS-CoV-2交叉保护和免疫学视角的见解
Weikai Dong and others
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1081–e1082, https://doi.org/10.1093/infdis/jiag080
56
When PD-1 Meets Plaque: Making CD8 Senescence Signals Clinically Actionable in Treated HIV
当PD-1遇上斑块：使治疗后的HIV感染者中CD8细胞衰老信号具有临床可操作性
Xiaowei Zhang
The Journal of Infectious Diseases, Volume 233, Issue 4, 15 April 2026, Pages e1083–e1084, https://doi.org/10.1093/infdis/jiag081
The Journal of Infectious Diseases. Volume 233 Issue 5
传染病杂志 233卷 5期
https://academic.oup.com/jid/issue/
Editorial（社论）
1
Beyond Transplantation: Cytomegalovirus Viremia as a Therapeutic Target in Non-Cytomegalovirus Syndromes
超越移植：巨细胞病毒血症作为非巨细胞病毒综合征的治疗靶点
Ghady Haidar
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 799–801, https://doi.org/10.1093/infdis/jiaf648
2
When Time Is of the Essence: Hepatitis C Virus RNA Point-of-Care Testing in 15Minutes Becomes a Reality
当时间至关重要：15分钟内完成丙型肝炎病毒RNA即时检测成为现实
Tanya L Applegate and Jason Grebely
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 802–805, https://doi.org/10.1093/infdis/jiaf652
Trainee’s Corner（实习生专栏）
3
The Day I Was Told I Wasn’t Doing Science—And Why I’m Grateful for It
被告知我没有在做科学的那一天——以及我为何对此心怀感激
Sara Gianella
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 806–808, https://doi.org/10.1093/infdis/jiaf614
JID Viewpoint（《传染病杂志》观点）
4
Restoring TB-specific Immunity in Early HIV Infection—the Dual Promise of Early Antiretroviral and TB Preventive Treatment
在HIV感染早期恢复结核特异性免疫——早期抗逆转录病毒治疗与结核预防性治疗的双重前景
Patrick K Moonan and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 809–811, https://doi.org/10.1093/infdis/jiaf518
Major Articles and Brief Reports（主要论著与简报）
Viral Disease Pathogenesis（病毒性疾病发病机制）
5
Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes
需要补充氧疗的住院成人SARS-CoV-2感染患者中的巨细胞病毒DNA血症：病毒学与临床特征及其与预后的关系
Michael Boeckh and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 812–822, https://doi.org/10.1093/infdis/jiaf649
6
Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System
基于DASH快速聚合酶链反应系统的丙型肝炎病毒RNA快速自动化即时检测的开发
Jennifer L Reed and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 823–830, https://doi.org/10.1093/infdis/jiaf608
7
Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C
纤维炎症活动血清标志物PRO-C3和CPa9-HNE与慢性丙型肝炎患者肝脏相关预后有关
Emilie Toft Skovgaard and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 831–839, https://doi.org/10.1093/infdis/jiaf552
8
A Rapid Assay for Hepatitis C Virus RNA Detection Using Reverse-Transcription Loop-Mediated Isothermal Amplification–Coupled CRISPR-Cas12b–Based Strategy
基于逆转录环介导等温扩增联合CRISPR-Cas12b策略的丙型肝炎病毒RNA快速检测方法
Avisha Chowdhury and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 840–847, https://doi.org/10.1093/infdis/jiaf609
9
Maternal-Fetal Letermovir Exposure In Vivo and Physiologically Based Pharmacokinetic Modeling: A Rationale for Congenital Cytomegalovirus Therapy
体内母胎来特莫韦暴露及生理药代动力学建模：先天性巨细胞病毒治疗的理论基础
Valentine Faure Bardon and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 848–857, https://doi.org/10.1093/infdis/jiaf619
10
Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems
使用两种现代递送系统进行雾化流感病毒人体激发的可行性与安全性
Nadine Rouphael and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 858–867, https://doi.org/10.1093/infdis/jiaf603
11
Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study
住院成人患者中与鼻病毒相关的下呼吸道感染：一项回顾性队列研究
Rongling Zhang and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 868–876, https://doi.org/10.1093/infdis/jiaf651
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
12
Decoding Hypervirulence in Carbapenem-Resistant Klebsiella pneumoniae: Genomic and Phenotypic Profiling Reveals Capsular Polysaccharide as a Key Driver of Pathogenicity
解码碳青霉烯耐药肺炎克雷伯菌的高毒力：基因组与表型分析揭示荚膜多糖是致病性的关键驱动因素
Li Xu and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 877–887, https://doi.org/10.1093/infdis/jiag075
13
Inflammatory Cytokine Profile in Pregnant Women Colonized With Group B Streptococcus Reveals IL-17a as a Potential Biomarker to Identify at-risk Newborns
B族链球菌定植孕妇的炎症细胞因子谱显示IL-17a可作为识别高危新生儿的潜在生物标志物
Narjis Amar and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 888–898, https://doi.org/10.1093/infdis/jiag092
14
Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection
表位基多聚体亚单位疫苗（ATOMSSUISpenta）对猪链球菌感染提供广泛保护
Sun-Young Kim and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 899–911, https://doi.org/10.1093/infdis/jiag131
Parasites（寄生虫）
15
Pfs230 Domains 7–10 Encoded by DNA Vaccines Induce Potent Complement-Independent Transmission-Blocking Antibody Against Plasmodium falciparum
DNA疫苗编码的Pfs230结构域7–10可诱导强效非补体依赖性抗恶性疟原虫传播阻断抗体
Yi Cao and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 912–923, https://doi.org/10.1093/infdis/jiaf555
16
Uneven Plasmodium falciparum Transmission and Cryptic ovale Transmission From the Asymptomatic Reservoir in Bagamoyo, Tanzania
坦桑尼亚巴加莫约无症状感染库中恶性疟原虫传播不均与隐匿性卵形疟原虫传播
Jessica T Lin and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 924–933, https://doi.org/10.1093/infdis/jiaf634
17
Mzb1 Promotes Progression of Schistosomiasis by Inducing Endoplasmic Reticulum Stress
Mzb1通过诱导内质网应激促进血吸虫病进展
Lanyue Pan and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 934–945, https://doi.org/10.1093/infdis/jiaf639
Antimicrobial Resistance (AMR)（抗生素耐药）
18
Longitudinal Trends in Pediatric Non-Salmonella Gram-Negative Enterobacterales Infections at a Tertiary Care Center in West Africa, 2005–2023
西非一家三级医疗中心2005–2023年儿童非沙门氏菌革兰阴性肠杆菌科感染的纵向趋势
Sumanth Cherukumilli and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 946–956, https://doi.org/10.1093/infdis/jiag027
19
The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital
阿奇霉素5天疗程对出院肯尼亚儿童肺炎链球菌携带率及抗菌药物耐药性的影响
Tanya E Libby and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 957–965, https://doi.org/10.1093/infdis/jiag028
20
Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study
高剂量双联方案一线幽门螺杆菌根除治疗的比较分析：一项逆概率加权多中心研究
Qingzhou Kong and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages 966–974, https://doi.org/10.1093/infdis/jiag059
Editorial（社论）
21
Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research
实施并非在真空中发生：维持全面且全球化的HIV研究愿景
Sara Gianella and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1085–e1087, https://doi.org/10.1093/infdis/jiag063
22
Uncovering the Hidden Impacts of Modern Medicine's Expanding Pharmacopeia on Clostridioides difficile Infection Risk
揭示现代医学不断扩展的药物谱对艰难梭菌感染风险的隐性影响
Alison Laufer Halpin and L Clifford McDonald
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1088–e1091, https://doi.org/10.1093/infdis/jiag011
Perspectives（观点）
23
Future Directions for NIH HIV Research: A Look Ahead to 2026
美国国立卫生研究院HIV研究的未来方向：展望2026年
Geri R Donenberg and Robert W Eisinger
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1092–e1093, https://doi.org/10.1093/infdis/jiag062
ID Translational Science Update（传染病转化医学更新）
24
Immune Responses to Phage Therapy in Humans: A Review
人体对噬菌体疗法的免疫应答：综述
Kiran Bosco and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1094–e1103, https://doi.org/10.1093/infdis/jiag096
Major Articles and Brief Reports（主要论著与简报）
Bacterial Disease Pathogenesis（细菌性疾病发病机制）
25
Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study
与艰难梭菌感染风险相关的抗菌及非抗菌药物：一项全药物谱病例-队列研究
Kevin A Brown and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1104–e1114, https://doi.org/10.1093/infdis/jiag001
26
Age-Specific Concentrations and Seroprevalence of Antibodies Against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) Across 3 Sites in Kenya
肯尼亚3个地区针对鼠伤寒沙门氏菌（O:9）和伤寒沙门氏菌（O:4,5）抗体的年龄特异性浓度与血清流行率
Esther M Muthumbi and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1115–e1123, https://doi.org/10.1093/infdis/jiag114
27
Influence of Chlamydia trachomatis Sequence Variation on pgp3 Antigenicity
沙眼衣原体序列变异对pgp3抗原性的影响
Filomeno Coelho da Silva and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1124–e1129, https://doi.org/10.1093/infdis/jiag067
28
Increased Diversity and Introduction of Multidrug-Resistant Strains of Neisseria gonorrhoeae Following Cessation of COVID-19 Pandemic–Related Travel Restrictions: An Observational Genomic Epidemiologic Study
新冠疫情相关旅行限制解除后淋病奈瑟菌多样性增加及多重耐药菌株的引入：一项观察性基因组流行病学研究
Rosa C Coldbeck-Shackley and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1130–e1140, https://doi.org/10.1093/infdis/jiag097
29
Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity
致病性减弱的肺炎链球菌生物合成基因突变体可侵入黏膜上皮并诱导先天免疫
Caroline M Weight and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1141–e1153, https://doi.org/10.1093/infdis/jiag124
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
30
Functional and Transcriptional Senescence Profiles of CD8+ T Cells Associate With the Presence of Carotid Plaques in People Living With HIV
HIV感染者中CD8+ T细胞的功能及转录衰老特征与颈动脉斑块有关
Marc J T Blaauw and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1154–e1164, https://doi.org/10.1093/infdis/jiag018
31
Estimating HIV-1 Viremic Time From Reservoir Sequence Diversity With Uncertainty Quantification
利用库序列多样性估算HIV-1病毒血症时间及不确定性量化
Edward N Kankaka and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1165–e1172, https://doi.org/10.1093/infdis/jiag020
32
Longitudinal Changes in Cognition and Brain Imaging in Persons With Human Immunodeficiency Virus
人类免疫缺陷病毒感染者认知功能与脑影像学的纵向变化
James Kennedy and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1173–e1180, https://doi.org/10.1093/infdis/jiag029
Antimicrobial Resistance (AMR)（抗生素耐药）
33
Epidemiological and Molecular Surveillance of Multiresistant Citrobacter freundii Complex in a Tertiary Care Hospital: A Retrospective Cohort Study
三级医疗机构中多重耐药弗氏柠檬酸杆菌复合群的流行病学与分子监测：一项回顾性队列研究
Pérince Fonton and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1181–e1192, https://doi.org/10.1093/infdis/jiag066
34
The Influence of National Antibiotic Consumption on Neisseria Gonorrhoeae Antibiotic Resistance in Norway, 2003–2024
2003–2024年挪威全国抗生素消耗对淋病奈瑟菌耐药性的影响
Patricia Campbell
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1193–e1202, https://doi.org/10.1093/infdis/jiag076
35
Restoration of Mucosa-Associated Invariant T-Cell Function in Healthcare-Associated Bacterial Infections Supports Recovery of Carbapenem Efficacy Against Resistant Bacteria Ex Vivo
医疗相关细菌感染中黏膜相关恒定T细胞功能的恢复支持碳青霉烯类药物对耐药菌疗效的体外恢复
Yiting Xue and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1203–e1214, https://doi.org/10.1093/infdis/jiag151
Parasites（寄生虫）
36
Febrile Temperature Augments Ring-stage Plasmodium falciparum Adhesion to Brain Endothelial Cells
发热温度增强环期恶性疟原虫对脑内皮细胞的黏附
Fatou Joof and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1215–e1225, https://doi.org/10.1093/infdis/jiaf474
37
Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial
6-重氮-5-氧代-L-正亮氨酸在马拉维有无疟疾成年人群中的安全性、耐受性与药代动力学：一项1期剂量递增临床试验
Brittany A Riggle and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1226–e1237, https://doi.org/10.1093/infdis/jiag121
38
Tracking Plasmodium knowlesi Through Fecal DNA for Monitoring Zoonotic Transmission in Wild Macaques Across Southeast and South Asia
通过粪便DNA追踪诺氏疟原虫以监测东南亚和南亚野生猕猴中的人畜共患传播
Dhammika Leshan Wannigama and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1238–e1243, https://doi.org/10.1093/infdis/jiag128
Viruses（病毒）
39
Effectiveness of Measles-Mumps-Rubella Vaccination Among Persons Residing in a Congregate Migrant Shelter During a Measles Outbreak: An Observational Cohort Study
麻疹爆发期间聚集性移民收容所居住者麻疹-腮腺炎-风疹疫苗的有效性：一项观察性队列研究
Chelsea S Lutz and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1244–e1252, https://doi.org/10.1093/infdis/jiaf650
40
Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana
量化加纳从Rotarix转换为Rotavac轮状病毒疫苗的影响
Ernest O Asare and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1253–e1260, https://doi.org/10.1093/infdis/jiag003
41
Persistent T Cell Immunity Following Nipah Virus Infection: Evidence From Malaysian Survivors
尼帕病毒感染后T细胞免疫的持续存在：来自马来西亚幸存者的证据
Puteri Ainaa S Ibrahim and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1261–e1266, https://doi.org/10.1093/infdis/jiag017
42
Characterization of Mouse-Adapted Marburg and Ravn Viruses in Inbred BALB/c and Outbred CD-1 Mice
BALB/c近交系与CD-1远交系小鼠中适应小鼠的马尔堡病毒与拉文病毒的特征研究
Katherine A Davies and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1267–e1272, https://doi.org/10.1093/infdis/jiag019
43
Cross-reactive H5N1 Neuraminidase Antibodies by Age and Influenza A Imprinting Cohorts of the Past Century: Population-Based Serosurvey, British Columbia, Canada
过去一个世纪不同年龄与甲型流感印记队列中H5N1神经氨酸酶交叉反应抗体：加拿大不列颠哥伦比亚省人群血清学调查
Danuta M Skowronski and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1273–e1284, https://doi.org/10.1093/infdis/jiag030
44
Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound
SARS-CoV-2感染及症状反弹中的炎症小体激活与氧化应激
Silvia Lucena Lage and others
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1285–e1297, https://doi.org/10.1093/infdis/jiag037
Letters to the Editor（致编辑的信）
45
Reply to Gianella: Redefining Science Together
致Gianella的回复：共同重新定义科学
Rachel A Bender Ignacio
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1298–e1299, https://doi.org/10.1093/infdis/jiaf644
46
Response to the Day I Was Told I Wasn’t Doing Science—And Why I’m Grateful for It
对《被告知我没有在做科学的那一天——以及我为何对此心怀感激》的回应
Darcy Wooten
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Page e1300, https://doi.org/10.1093/infdis/jiag084
47
Reply to Gianella: Women in Academic Medicine Will Lead a Sea Change
致Gianella的回复：女性学者将引领学术医学的海变
Maile A Y Karris
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Page e1301, https://doi.org/10.1093/infdis/jiag109
48
Between Two Standards: Reflections on the Double Bind From a Female Chinese Infectious Disease Physician
两种标准之间：一位中国女性传染病医生对双重束缚的反思
Nan Xu
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1302–e1303, https://doi.org/10.1093/infdis/jiag101
49
When “Logistics”Becomes Science: A Research Coordinator's Response on Team-Based Discovery
当"后勤"变成科学：一位研究协调员关于团队协作发现的回应
Cheryl Dullano
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Page e1304, https://doi.org/10.1093/infdis/jiag102
50
Pushing the Stone Uphill Together
共同推石上山
Scott L Letendre
The Journal of Infectious Diseases, Volume 233, Issue 5, 15 May 2026, Pages e1305–e1306, https://doi.org/10.1093/infdis/jiag125
2026-05-19
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
100 项与 盐酸利匹韦林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2011-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 怀孕 | 临床3期 | 美国 | 2009-04-09 | |
| 肝炎 | 临床1期 | 美国 | 2011-11-01 | |
| 丙型肝炎 | 临床1期 | - | 2010-11-01 | |
| 避孕 | 临床1期 | - | 2008-07-01 | |
| 避孕行为 | 临床1期 | - | 2008-07-01 | |
| 获得性免疫缺陷综合征 | 临床1期 | - | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 306 | 遞糧衊繭醖鹹範夢獵壓(餘鬱鹽艱獵繭蓋餘顧鑰) = 襯憲夢製願觸繭網糧壓 襯淵顧糧鹽夢製鬱廠願 (鹽壓鹹遞膚餘壓鹽範壓 ) 更多 | 积极 | 2026-02-26 | |||
Standard care | 遞糧衊繭醖鹹範夢獵壓(餘鬱鹽艱獵繭蓋餘顧鑰) = 夢顧製顧觸鹹壓齋壓壓 襯淵顧糧鹽夢製鬱廠願 (鹽壓鹹遞膚餘壓鹽範壓 ) 更多 | ||||||
临床3期 | 396 | Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV | 醖淵獵膚選鑰廠蓋構積(夢構範壓觸積蓋蓋蓋範) = 鏇衊製衊廠窪觸鑰鏇齋 膚鬱襯壓衊積襯顧衊蓋 (觸繭繭夢襯蓋鬱網廠憲 ) 更多 | 积极 | 2025-12-01 | ||
醖淵獵膚選鑰廠蓋構積(夢構範壓觸積蓋蓋蓋範) = 淵艱醖鏇繭選選繭醖遞 膚鬱襯壓衊積襯顧衊蓋 (觸繭繭夢襯蓋鬱網廠憲 ) 更多 | |||||||
临床3期 | 145 | 獵鏇襯鹽鏇壓顧顧糧醖(膚簾膚廠膚鏇廠構窪糧) = 遞憲艱顧願憲壓積網觸 繭齋顧鹹廠淵壓憲衊構 (製齋觸憲選蓋鑰願夢觸 ) 更多 | 积极 | 2025-07-14 | |||
临床3期 | 456 | (Step 2 Arm A: LA ART) | 蓋簾鹽夢鹽製願齋糧鬱 = 範鹹鑰淵簾遞網鬱簾鹹 衊醖餘壓鏇憲製艱鹽艱 (製廠衊齋選齋蓋願糧窪, 壓選遞餘廠顧繭觸範鑰 ~ 鹹範鬱糧淵願範淵鑰繭) 更多 | - | 2025-04-24 | ||
Standard of Care (SOC) Oral ART (Step 2 Arm B: SOC) | 蓋簾鹽夢鹽製願齋糧鬱 = 蓋憲製構遞鹽觸願繭鬱 衊醖餘壓鏇憲製艱鹽艱 (製廠衊齋選齋蓋願糧窪, 顧衊廠築壓廠餘襯夢蓋 ~ 憲窪醖構構鹽餘鑰壓遞) 更多 | ||||||
临床1/2期 | 139 | 鬱餘壓繭窪艱憲醖襯遞(選遞廠憲築繭壓獵鬱繭) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 糧艱衊醖齋鏇鑰壓構選 (艱鹹觸簾網壓鹽艱壓鹹 ) 更多 | 积极 | 2025-03-01 | |||
临床2期 | 54 | (Cohort 1 Adolescents: Rilpivirine 25 mg) | 簾襯築鬱簾鏇壓鏇廠鬱(鹽獵餘憲構鏇齋網願窪) = 廠鹹膚壓襯築構選積襯 獵壓醖積獵窪淵獵簾選 (簾膚齋築鏇願觸艱壓齋, 38.0) 更多 | - | 2024-06-25 | ||
(Cohort 2 Children (>=25 kg): Rilpivirine 25 mg) | 簾襯築鬱簾鏇壓鏇廠鬱(鹽獵餘憲構鏇齋網願窪) = 鹽衊積積鬱膚願憲構簾 獵壓醖積獵窪淵獵簾選 (簾膚齋築鏇願觸艱壓齋, 52.2) 更多 | ||||||
临床1/2期 | 168 | Combination Antiretroviral Therapy (cART)+Long-Acting Injectable Cabotegravir (CAB LA) (Cohort 1C: CAB) | 範糧餘獵範顧獵顧繭窪 = 範範淵鬱選壓膚憲積齋 鑰衊齋醖廠衊網繭壓鏇 (蓋艱網窪繭選糧鑰艱蓋, 齋網繭鹽網襯齋淵遞顧 ~ 襯鏇願蓋願積構襯構獵) 更多 | - | 2024-05-14 | ||
Combination Antiretroviral Therapy (cART)+RPV (Cohort 1R: RPV) | 窪鹹範蓋鏇齋窪觸醖夢 = 選顧簾構願窪窪醖網窪 糧窪夢衊積壓壓壓壓鹽 (鑰築襯築鏇範構製餘艱, 願鏇網淵襯襯蓋網範餘 ~ 壓鑰壓淵壓鑰鹹糧夢鬱) 更多 | ||||||
临床2期 | 26 | (Rilpivirine 12.5 Milligrams (mg) (<20 kg)) | 鏇願廠鏇膚願鬱艱糧鏇(顧鏇網鹽壓獵廠繭簾廠) = 觸膚憲齋鑰繭鑰構築顧 鹹鹽廠顧醖願簾襯廠選 (廠鹹蓋憲齋顧壓顧憲壓, NA) 更多 | - | 2024-05-02 | ||
(Rilpivirine 15 mg (<20 kg)) | 鑰窪繭鹽積夢鹽窪鹽築(鹹艱淵選積構簾鹹艱製) = 網網簾齋鹽願鏇糧構廠 壓簾願餘繭簾餘遞鏇繭 (選淵膚構獵憲鏇簾齋遞, NA) 更多 | ||||||
临床1期 | 15 | (IM CAB 600 mg) | 襯觸觸糧繭糧鏇淵獵蓋(窪衊願範築積遞壓範觸) = 襯繭醖襯蓋壓網願窪築 襯繭齋壓鹽選觸廠衊鹽 (憲衊膚齋選衊顧繭顧蓋, 66) 更多 | - | 2024-04-22 | ||
(IM RPV 900mg) | 膚範餘襯襯衊構構壓衊(夢憲糧窪膚衊鏇範醖網) = 蓋壓鏇積壓選範齋範齋 夢鑰簾醖鏇廠醖鏇淵廠 (範壓糧齋鏇觸範夢願積, 37.7) 更多 | ||||||
临床2期 | - | EDURANT+BR (HIV RNA ≤100,000) | 夢構製醖鹹繭膚積襯艱(蓋獵艱鏇齋淵製膚窪構) = 淵壓範鹹憲廠襯淵襯鏇 簾齋憲鹹製鏇獵構醖艱 (夢鏇鬱製鹽艱築鬱製夢 ) 更多 | 优效 | 2024-03-15 | ||
EDURANT+BR (HIV RNA >100,000) | 夢構製醖鹹繭膚積襯艱(蓋獵艱鏇齋淵製膚窪構) = 製繭淵衊鹹製憲構願餘 簾齋憲鹹製鏇獵構醖艱 (夢鏇鬱製鹽艱築鬱製夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用